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Small molecule dependent molecular switches that control gene expression are 
important tool in understanding biological cellular processes and for regulating gene 
therapy. Nuclear receptors are ligand activated transcription factors that have been 
engineered to selectively respond to synthetic ligands and used as regulators of gene 
expression. In this work the retinoid X receptor (RXR), has been used to develop an 
inducible molecular switch with a near drug like compound LG335. Three RXR variants 
(Q275C; I310M; F313I), (I268A; I310A; F313A; L436F), (I268V; A272V; I310M; 
F313S; L436M) were created via site-directed mutagenesis and a structure based 
approach, such that they preferentially bind to the synthetic ligand LG335 and not its 
natural ligand, 9-cis retinoic acid. These variants show reverse ligand specificity as 
designed and have an EC50 for LG335 of 80 nM, 30 nM, 180 nM, respectively. The 
ligand binding domains of the RXR variants were fused to a yeast transcription factor 
Gal4 DNA binding domain. This modified chimeric fusion protein showed reverse 
response element specificity as designed and recognized the Gal4 response element 
instead of the RXR response element. The modified RXR protein did not heterodimerize 
with wild type RXR or with other nuclear receptor such as retinoic acid receptor. These 
RXR-based molecular switches were tested in retroviral vectors using firefly luciferase 
and green fluorescence protein and they maintain their inducible behavior with LG335. 
These experiments demonstrate the orthogonality of RXR variants and their possible use 










Gene therapy has developed into a promising therapeutic to treat a diverse array 
of diseases such as cancer, AIDS, cystic fibrosis, Parkinson’s, Alzheimer’s, 
cardiovascular disease and arthritis. This technology of gene therapy uses functional 
genes to provide a desired treatment. Gene therapy has become effective due to the 
advances in gene delivery systems and gene regulatory systems. The gene regulatory 
system is an important aspect of gene therapy because over or under-production of the 
therapeutic protein can cause side effects. Some regulatory systems have been developed 
to control gene expression in vitro and in vivo. Initial attempts to regulate gene 
expression have used endogenous cellular elements such as promoter and enhancer that 
respond to physiological changes such as heat[1], metal ions[2], interferons[3] and 
hypoxia[4]. Other regulatory systems such as the lac operator-IPTG-based system[5-8], 
the FKB12-rapamycin-associated protein/FK106 binding protein[9] and mRNA aptamer 
based system[10] have also been developed. Many of these systems are not suitable for 
clinical gene therapy for reasons such as toxicity, lack of specificity and background 
transcriptional activity in the uninduced state.  
Inducible gene expression systems have been developed that are regulated by 
administration of specific small molecules or ligands. These ligand-dependent inducible 
systems are usually based on two components: the first component is a chimeric 
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transcription factor containing a DNA-binding domain (DBD) fused to a ligand binding 
domain (LBD), where the DBD recognizes a DNA sequence; the second component is an 
artificial promoter consisting of binding sites for the DBD followed by a minimal 
promoter and the therapeutic gene (Figure 1.1). The genetically engineered transcription 
factors used in these systems are generally derived from bacterial repressor proteins or 
eukaryotic receptors. The engineered transcription factors function as molecular switches, 
i.e. they are either turned on or off in the presence of a suitable ligand. To utilize these 
switches for gene therapy, genes encoding for the molecular switch and the therapeutic 
gene will be delivered to the patient. In the presence of the ligand the molecular switch 
will be recruited to the artificial promoter and express the therapeutic gene downstream 
of this promoter (Figure 1.2).  This thesis focuses on developing  new molecular switches 
to control gene expression using small molecules.  
The molecular switches that are currently being developed can control three 
processes: transcriptional activation, translational initiation and posttranslational protein 
activity. Among the transcriptional switches, several researchers have tried creating DNA 
binding protein to bind arbitrarily chosen DNA sequence[11, 12]. One of the earlier 
works was done by Barbas, Schultz and coworkers[13, 14]. They engineered the natural 
zinc finger protein Zif268, to bind to DNA in the presence of a small molecule ligand. 
They evolved zinc fingers that bind to individual GNN codons[15]. Two residues, 
histidine 125 and phenylalanine 116, which participate in zinc binding, were mutated to 
an alanine and a glycine resulting in a cavity around the zinc ion and abolishing 
transcriptional activation. They used the bump-hole approach[16-18] to alter ligand  
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Figure 1.1 Ligand dependent inducible systems. 
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binding specificity and screened 250 heterocyclic molecules. They found a small 
molecule 2-(4-quinoline)-benzimidazole, that increased gene activity by 18 fold. The 
small molecule bound mutant protein recognizes the DNA site with increased affinity. 
The fusion of three Zif268 proteins to the VP16 activation domain and the estrogen 
receptor LBD created transcriptional switches[14]. Another example of transcription 
switch based on the DNA binding protein is tetracycline repressor (TetR). Hillen and 
coworkers created an orthogonal regulatory system in eukaryotics cells by incorporating 
elements of the tetracycline-resistance operon[19, 20]. TetR was fused to a herpes 
simplex virus (HSV) VP16 transactivation domain to form a tet-controlled transactivator 
(tTA). This chimeric protein could control transcription in mammalian cells from a tet-
responsive control element consisting of tet operators fused to a minimal promoter. In the 
presence of tet, tTA is unable to bind operator sequences to activate transcription, making 
this a tet-repressible system. One of the drawbacks of this tTA system is that tetracycline 
must be present to keep gene expression repressed. To overcome this problem directed 
evolution approach was used to create TetR mutants that bind the operator in the presence 
of tetracycline or a derivative doxycycline. Correspondingly, the reverse tet transactivator 
(rtTA) activates gene expression in the presence of either drug, rendering the system 
more suitable for therapeutic applications[20]. 
In contrast to altering the DNA binding domain, researchers have made efforts to 
create molecular switches by altering the ligand specificity of the activation domain. 
Nuclear receptors are extensively used to generate orthogonal ligand receptor pairs to 
control gene expression. Parker and coworkers created orthogonal mutants of estrogen 
receptor (ER) LBD. They created a mutant glycine 521 arginine  that is induced by 4-
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hydroxytamoxifen by 10 fold and does not respond to its natural ligand β-estradiol[21, 
22]. Crystal structure of ER LBD with β-estradiol and 4-OHT reveals that the side chain 
of arginine 521 reduces the cavity size hindering β-estradiol to bind, while 4-OHT 
remains unaffected.  In another systems developed by O’Malley and colleagues, 
progesterone receptor LBD was modified. It was based on the truncated progesterone 
receptor ligand-binding domains (PR-LBD). This modified PR-LBDs lost the ability to 
respond to its natural ligand progesterone, but have gained the ability to respond to 
antiprogestins as agonists, rather than as antagonists[23]. This modified PR-LBD is fused 
to yeast Gal4 DNA binding domain and an activator domain such as VP16 or hNF-КB 
p65. The inducible target gene has a minimal promoter that consists of multiple binding 
sites for the Gal4 DBD. Binding of the antiprogestin inducer mifepristone triggers a 
conformational change that causes the regulator protein to become an activated 
homodimer, which binds to Gal4 sites in the inducible promoter stimulating transcription 
of the target gene[24, 25]. 
Schreiber and Clackson pioneered the strategy of creating molecular switches 
using chemical inducers of dimerization (CID)[26].  Here the transcription is controlled 
by using two separate protein components, a DNA binding domain (DBD) and an 
activation domain (AD), each fused to a small molecule binding domain[27, 28]. In the 
presence of a small molecule, both fusion proteins bind the small molecule, recruiting the 
activation domain to the promoter of interest. The most widely used chemical dimerizer 
system is FK506-binding protein (FKBP) and FRAP which binds to a ligand rapamycin. 
In one application two fusion proteins was constructed, one being FRB (FKBP and 
rapamycin binding domain of FRAP) fused to the transcriptional activator from NF-κB 
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and the other was a zinc finger DBD, ZFHD1 fused three repeats of FKBP as the second 
protein. In the presence of both rapamycin and the target gene containing the binding site 
for ZFHD1, the transcription increased by more then 10000 fold[9]. 
Translational switches are another way of regulating gene expression. Breaker 
and coworkers are the pioneers in discovering translational switches. They discovered 
RNA-mediated small molecules termed riboswitches that regulate translation[29]. These 
riboswitches are found in the 5’-untranslated region of mRNA. They contain two 
domains, an aptamer region that binds to a metabolite and an expression platform that 
interacts with regulatory elements in the mRNA, such as the Shine-Dalgarno sequence. 
Riboswitches can be turned on and off through allosteric regulation by ligands. The 
mechanism by which gene expression is regulated involves the formation of alternative 
structures that, in the repressing conformation, cause premature termination of 
transcription or inhibition of translation initiation. These riboswitches regulate several 
metabolic pathways including the biosynthesis of vitamins, metabolism of methionine, 
lysine and purines[30]. Hillen and coworkers designed an artificial riboswitch using RNA 
aptamer for theophylline and structural bridge evolved by Breaker[31] such that upon 
addition of theophylline, a conformational change occurs and translation is increased by 
eight fold[32]. This was the first riboswitch that increased translation rather then 
repressing it. 
 Some ligand dependent switches that act posttranslationally are based on protein 
splicing. Trans-splicing is a phenomenon in which an intein is split into inactive N- and 
C- terminal halve, when combined these halves reconstitute an active intein that is 
capable of splicing. Muir developed a trans-splicing system in which two intein 
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fragments are brought together by addition of rapamycin[33]. Three previously 
developed molecular switches that are commonly used to date and are similar to the one 
developed in this thesis are now reviewed in detail. 
 
Progesterone receptor regulatory system 
 
  Recently, a progesterone receptor (PR) mutant with a C- terminal truncation was 
isolated that prevents binding with the natural ligand progesterone[24, 25]. The truncated 
receptor retains the ability to bind the antagonist mifepristrone (RU 486). Mifepristrone 
(known for abortive function in humans) acts as an inducer on the mutant PR and 
promotes transcription of target genes containing progesterone responsive elements[34]. 
Wang and coworkers made modifications to the PR to increase its sensitivity to 
mifepristrone and  to create a ligand inducible gene expression system[25].  These 
modifications allowed PR to respond to mifepristrone at concentrations one order of 
magnitude lower than those needed to cause an abortive activity[24]. The truncated PR 
with 10 to 34 glutamine residues was fused with the Gal4 DNA binding domain (a yeast 
transcription factor) and a eukaryotic transcriptional activation domain from viral protein 
(VP), VP16 or the p65 subunit of human NF-ĸB. This chimeric transcription factor and 
its inducer, mifepristrone could now regulate the expression of target gene with a Gal4 
binding site[35]. To reverse the mifepristrone responsiveness behavior  the VP16 domain 
was replaced by the KRAB motif (krüppel-associated box protein), a potent repressor 
domain of the kidney-specific transcription factor Kid-1[23]. Using this KRAB-
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containing transrepressor resulted in mifepristrone dependent repression of target 
genes[25]. 
The advantage of this system is that the majority of the system comprises 
modified human proteins and does not provoke an immune response. The disadvantage is 
that despite various improvements, the regulation performance of mifepristrone-based 
systems in mammalian cells remains relatively poor, due to the high basal activity in an 
uninduced state. The high basal activity results in a low induction ratio, generally about 
20 folds. Also, mifepristrone may affect the ovarian cycle and exert a contraceptive 
activity.  
 
  Ecdysone receptor regulatory systems 
 
 Ecdysone receptor (EcR) is an insect steroid hormone receptor, that functions as a 
heterodimer of the ecdysone receptor (EcR) and the ultraspiracle protein (USP)[36]. EcR 
triggers metamorphosis in Drosophila melanogaster and other insects. The class of 
ligands that bind the EcR are called ecdysteroids[37]. Modifications were made to the 
EcR to create a molecular switch. The N-terminal activation domain of EcR was replaced 
by the corresponding domain of glucocorticoid receptor (GR), its natural heterodimeric 
partner USP, was replaced by its mammalian homologue Retinoid X receptor (RXR). 
These modification resulted in a 34-fold induction of the target gene[38]. However the N-
terminal truncated EcR fused to the VP16 (VpEcR) heterodimerizing with RXR 
increased the induction ratio to 212-fold[38]. To minimize the potential interference with 
endogenous factors, the specificity of VpEcR and its binding site was further improved. 
 9
VP16-EcR- GR (VgEcR)/RXR heterodimer  and a synthetic binding site consisting of a 
hybrid between the GR, EcR and RXR for (VgEcR)/RXR complexes were 
constructed[38].  
  An advantage of EcR based regulatory system is the low level of basal activity as 
compared to other inducible systems. The low basal activity results in high induction 
level of the target gene. Despite of many advantages over other systems, it has several 
shortcomings that may prevent its use in gene therapy applications. Firstly, insect 
hormones and their agonists are not orally bioavailable and may not get approved for 
human therapeutic use. Secondly, this system requires simultaneous expression of two 
proteins VgEcR and RXR, which may complicates its use in certain viral delivery 
systems. Thirdly, over expression of mammalian RXR, may have pleiotropic effects in 
the mammalian cells. Finally,  RXR is a reluctant dimer partner of EcR, and very high 
endogenous levels of RXR are necessary for stimulation[36, 39].  
 
Tetracycline dependent regulatory system 
 
The tetracycline (Tet) dependent gene regulation system comprises of two 
complementary ideas known as the Tet-OFF and the Tet-ON system. This system is of 
prokaryotic origin and its core components are the Tet repressor (TetR), its cognate 
binding site, the tet operator, and an antibiotic tetracycline[19]. In bacteria, the TetR 
hinders transcription by docking on the Tet operator in the absence of tetracycline. In 
Tet- OFF system, a fusion of TetR and VP16 was made to convert tetR from a repressor 
to an activator termed tTA[40]. tTA interacts with its responsive promoter i.e. tandem 
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repeats of tet operator sequence and minimal promoter (TRE) to drive the expression of a 
target gene. In the presence of tetracycline, tTA is hindered to dock on its binding site 
TRE, thereby impeding transcription of the target gene. In Tet-ON system, random 
mutations were made in the tTA. Four amino acid changes yielded a protein that exhibits 
opposite function. This mutant, rtTA triggers activation of TRE controlled target gene 
only in the presence of tetracycline[20].  
The Tet system offers many advantages such as tetracycline and its analogue 
doxycycline is well characterized, safe, rapidly metabolized with a half-life of 14 to 22 
hours and nontoxic at doses required for gene activation in preclinical and clinical 
studies. Doxycycline is orally bioavailable, it has a good tissue penetration and does not 
interfere with native proteins[41]. Tet transcription factors are target specific i.e. tTA or 
rtTA docks only on TRE controlled target genes, hence reducing the risk of serious side 
effects. However, these proteins are prokaryotic in origin and may be immunogenic. 
Further study is required to determine whether the immune system can recognize 
components of the Tet system over the long time periods for the treatment of chronic 
illnesses such as Parkinson disease and multiple sclerosis.  
In the last decade, technologies for regulating gene expression in mammalian cells 
have advanced from cell lines to animal models. These technologies have impacted 
genomic research in an attempt to unravel molecular pathways. It has also contributed to 
the creation of animal models for currently untreatable human diseases, such as 
Parkinson's and Alzheimer's. Next generation gene regulation will have major challenges 
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including long-term applications, precise regulation of target genes over the lifetime of 






Nuclear receptors are a superfamily of eukaryotic ligand activated transcription 
factors that regulate development, cell proliferation, endocrine signaling and metabolism. 
Nuclear receptors comprise of a diverse super-family in terms of physiological roles 
ranging from receptors for regulating metabolic pathway such as uptake, oxidation, and 
processing of extracellular lipids to regulation of developmental pathways[42-44]. This 
super-family is composed of steroid receptors such as the ER, androgen receptor, the 
non-steroidal receptors such as the thyroid hormone receptor, retinoic acid receptor 
(RAR) and orphan receptors. Nuclear receptors are associated with numerous human 
diseases, for example, RARs with types of leukemia[45], ER with breast cancer, and 
peroxisome proliferator activated receptor with diabetes[43].   Hence, they have become 
a primary target of drug discovery and the pharmaceutical industry has a great interest in 
discovering agonist and antagonist for these receptors[46]. Some drugs that are currently 
used are tamoxifen against breast cancer, dexamethasone for inflammatory diseases and 
thiazolidinediones as drugs for type II diabetes[44].  
Nuclear receptors are ligand activated transcription factors that bind hydrophobic, 
fat-soluble small molecules. The role of the ligands can be to activate receptors or to 
deactivate constitutively active receptors. Structurally, nuclear receptors exhibit a 
modular structure with different domains corresponding to functional domains that can be 
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interchanged between related receptors without loss of function. Typically nuclear 
receptor consists of domains A-F, which consists of a variable NH2 – terminal domain 
(A/B), a conserved DNA binding domain known as C domain, a linker domain D, a 
conserved E domain that contains C-terminal ligand binding domain[43, 47], and a F 
domain (Figure 1.3). The A/B domain is variable in size and sequence and contains an 
AF-1 region which is a ligand-independent activation domain[48-50]. The DBD is highly 
conserved and has the ability to recognize specific DNA sequences known as the 
response element (RE)[44, 51]. Nuclear receptors regulate transcription by binding to a 
RE that is normally present within 1 kb to the promoter or in the enhancer region of the 
transcription. Analysis of a large number of RE’s revealed that a sequence of six base 
pairs constitutes the recognition motif.  Most receptors bind as homo- or heterodimers to 
REs to two core hexameric motifs. To form the dimer’s RE, the half-sites can be 
configured as palindromes, inverted palindromes, or direct repeats[52, 53]. This DBD or 
C domain comprises of two “zinc fingers”; each finger has four cysteines that coordinate 
one zinc ion[54]. Amino acids that are required for discrimination of DNA recognition 
motifs are present at the base of the first finger and the residues of the second zinc finger  
are involved in dimerization.  The D domain serves as a hinge between the DBD and the 
LBD, allowing flexibility between the LBD and DBD[43]. Nuclear receptors are modular 
proteins such that the DBD and LBD can function independent of each other. The E 
region or LBD is a multifunctional domain that in addition to the binding of the ligand 
mediates homo and heterodimerization [55]. The crystal structure of the LBDs of many 
nuclear receptors have been solved. Generally, the LBDs are formed by 12 conserved α-



















Figure 1.3 Nuclear receptor domains. 
 
 14
LBDs are folded into a three layered antiparallel helical sandwich[56].  Within the LBD a 
central core is formed called the ligand binding pocket which primarily consists of 
hydrophobic residues[56]. The size of the binding pocket varies among the different 
receptors. Several differences are evident in the LBD structures of a liganded and 
unliganded LBD. The ligand bound LBD is more compact, indicating there is a 
conformational change on ligand binding. 
In the absence of ligand the nuclear receptors recruit corepressor complexes. Co-
repressors do not bind to the DNA themselves but mediate gene silencing via DNA 
bound transcriptional factors[57]. Malfunctioning of co-repressor action can cause a 
variety of diseases such as human syndrome of resistance to thyroid hormone, familial 
type II diabetes based on reduced dissociation of the corepressor from peroxisome 
proliferator activated receptor γ.  The binding motif for two major co-repressors, nuclear 
receptor corepressor and the silencing mediator of retinoid and thyroid hormone receptor 
(SMRT) consists of the LXXI/LXXXI/L motif[57, 58]. It involves the recruitment of 
histone deacetylase (HDAC) which leads to a more compact chromatin structure which 
inhibits the accessibility of transcription factors and represses transcription[59-61]. 
Upon ligand binding, the nuclear receptor LBD undergoes a conformational 
change that involves several helices present in the LBD, especially helix 12.   In the apo 
form (unliganded) of the receptor, helix 12 is freely floating in the solution. In the holo 
form of the receptor helix 12 moves towards the protein and tightly packs against helix 3 
or 4 making direct contact with the ligand[62, 63]. The proper positioning of helix-12 
leads to formation of a hydrophobic cleft to create a proper dimerization interface for 
“LXXLL” NR-box sequences of transcriptional co-activators.  Ligand binding induces 
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recruitment of co activators complexes. Some of these proteins have histone 
acetyltransferase activity and interact with the transcription machinery[64]. This result is 
chromatin decompactation allowing RNA polymerase to initiate the transcription of 
target gene.  
 
 Retinoid X receptor 
   
 The human retinoid X receptor (RXR) is a ligand activated transcription factor 
of the nuclear receptor superfamily, under the subclass of retinoid receptors. RXR plays 
an important role in differentiation, homeostasis and morphogenesis. RXR has three 
isotypes RXRα, RXRβ, and RXRγ. It serves as a homodimer or as a dimerization partner 
for other nuclear receptors such thyroid receptor, vitamin D receptor [65, 66]. It is a key 
binding partner with retinoid acid receptor. Structurally, both RXR and RAR are similar 
to other nuclear receptors, containing a variable A/B region, the DBD, hinge region and 
LBD (Figure 1.3). The natural ligands known for RXR include phytanic acid[67], 
docosahexaenoic acid[68] and 9-cis retinoic acid (9cRA)[69]. The crystal structure of 
RXR bound to 9cRA is one of the first nuclear receptor to be solved and the key 
interactions of the binding pocket with the ligand were determined (Figure 1.4)[70]. 
When RXR homodimerizes it binds to a DNA sequence called RXR response element 
(RE). In the presence of 9cRA, RXR undergoes a conformational change, binds to RXR 
RE and initiates transcription of the gene downstream of RXR RE (Figure 1.5). This RE 
is a direct repeat of six bases with one base spacer  (DR1) such as CRBPII (TAGGTCA 











 Figure 1.4 Binding pocket of RXR with the residues that interact 








 Figure 1.5 Retinoid X receptor ligand binding domain binds to 9cRA 
  and RXR DNA binding domain recognizes RXR response element. 
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and LBD can function independently. Therefore, the LBD can be fused to other DBD’s 
and retain the function. This feature can be utilized to engineer the LBD such that it binds 
to synthetic ligand and fusing them to a foreign DBD would make an orthogonal ligand 
receptor pair. 
 
An orthogonal ligand receptor pair 
 
 The ability to manipulate protein to bind and respond to synthetic ligands in an 
orthogonal or independent manner is a challenge in protein engineering but an important 
tool for various biotechnology applications (Figure 1.6). The ability to control 
transcription using a ligand would be useful to study cellular processes such as apoptosis, 
signal transduction and facilitate the analysis of gene function during embryonic 
development and differentiation. It would reveal the function for thousand of genes that 
were discovered in various genome projects with unknown function. Creating such a 
matched ligand-receptor pair that is orthogonal can be utilized as molecular switches for 
inducible gene expression system. These molecular switches can be used for practical 
application such as gene therapy by regulating the expression of target gene. The 
molecular switches or orthogonal ligand receptor pair can be used as rheostats or as 
on/off switch depending on their response to the ligand. To utilize it for gene therapy, 
along with the therapeutic gene, the gene for orthogonal receptor would be delivered. 
The orthogonal receptor would be expressed in the cell and would bind to its 
specific response element that is present only in the promoter region of the therapeutic 




Figure 1.6 Schematic depiction of the interaction between wild type 
and orthogonal receptor with its natural or synthetic ligand. 
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gene to the desired level depending on the dose of the ligand and activation level of the 
receptor. Orthogonal ligand receptor pairs could also be utilized for enzyme engineering, 
where the receptor could be engineered to bind the desired product of an enzymatic 
reaction.  A library of engineered enzymes would be screened and when it produces the 
desired product, the product would behave as the ligand for the receptor and activate 
transcription of the reporter gene, thereby identifying the cell containing the desired 
enzyme. The gene expressing the desired enzyme would then be sequenced and 
recovered. 
 
Chemical complementation  
 
 Chemical complementation is a genetic selection system in which the survival of 
yeast or mammalian cells is linked to the ability of ligand binding and activation of the 
nuclear receptor RXR. It is a useful tool for engineering and selecting functional variants 
from libraries of receptors or to screen a library of compounds for a particular 
receptor[73]. Chemical complementation system is developed in yeast, where the PJ694A 
strain is engineered to contain Gal4 response element controlling the expression of ADE2 
gene (selection marker)[74]. Expression of the ADE2 gene allows the yeast to produce 
adenine and to survive in media lacking adenine. Gal4 RE is a short DNA sequence that 
is recognized by the DBD of a yeast ligand independent transcriptional activator Gal4 
protein. A fusion protein of RXR LBD and Gal4 DBD was constructed that would bind 
Gal4RE. Another fusion protein comprising of ACTR (nuclear receptor coactivator) and 
Gal4 activation domain is also expressed. In the presence of an                        
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agonist this fusion protein undergoes a conformational change and recruits the 
coactivator ACTR, Gal4DBD recognizes Gal4 RE which allows the transcription of 
ADE2 gene, resulting to the survival of yeast in adenine lacking media (Figure 1.7)[74]. 
Chemical complementation is a high throughput method for selecting novel ligand 
receptor pairs in a single experiment. This method is being developed in mammalian cells 
by using a positive and negative selection (details in chapter 5). Analogous to the yeast, 
mammalian cell line is engineered to contain Gal4 response element controlling the 
expression of triple fusion gene: neomycin resistant gene, reporter gene and thymidine 
kinase gene. A library of RXR variants fused to Gal4 DBD is expressed in the cells. In 
the presence of an agonist RXR undergoes a conformation change and expresses the 
triple fusion gene. In the presence of selective media such as geneticin and gancyclovir 
the cell containing the functional variants will survive and form colonies. These colonies 
can then be easily separated and evaluated by additional selection and/or screening 
assays. The variants that have high activation of the reporter gene in the presence of 
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INVESTIGATING ADDITIVITY OF MUTATIONS IN 






The ability to manipulate proteins to bind and respond to synthetic cell permeable 
small molecules is a significant challenge in protein engineering and an important tool for 
many biotechnology applications. The ability to control transcription using a ligand 
would be useful to study cellular processes such as apoptosis, signal transduction and 
facilitate the analysis of gene function during embryonic development and differentiation. 
Manipulating naturally occurring ligand-protein interactions can lead to the creation of 
orthogonal ligand receptor pairs (OLRP)[1]. OLRP must be orthogonal to the contents of 
the cell, meaning the receptor should not be activated by any endogenous small 
molecules and the ligand should not activate or interact with any endogenous proteins. 
Developing OLRPs can provide insights into the function of thousands of genes 
discovered in genome projects. It can be utilized to activate or repress transcription of 
specific gene by selective ligands, providing a useful tool to probe metabolic pathways.   
The retinoid X receptor (RXR) is a good candidate for creating variants that bind 
different ligands through site directed mutagenesis, because side chain atoms, not main 
chain atoms, contribute the majority of the ligand contacts[2]. RXR is a member of the 
nuclear receptor superfamily, under the class of retinoid receptors[3, 4]. RXR plays a 
crucial role in cell differentiation, development and maintenance of homeostasis. This 
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group of receptors when bound to a selective ligand can single handedly provide a 
transcriptional signal to specific target genes[5]. The known natural ligand of RXR is 9-
cis-retinoic acid (9cRA)[6]. RXR forms homodimers or heterodimers with other 
members of the nuclear receptor superfamily such as retinoid acid receptor (RAR), 
thyroid receptor, and vitamin D receptor[7]. The structure of RXR contains a variable N-
terminal region, DBD, hinge, and LBD (Figure 1.1)[4]. The crystal structure for 9cRA-
bound RXR has been solved and the residues that interact with the ligand have been 
identified (Figure 1.4)[8]. There are 20 hydrophobic and polar amino acids within 4.4 Å 
of the bound 9cRA[8].  
Peet and Doyle constructed a variety of RXR variants to alter its activation in 
response to various synthetic ligands to create an OLRP[2, 9]. An orthogonal ligand is a 
compound that is inactive as a wild type RXR agonist but active as a variant RXR 
agonist. One such orthogonal ligand that was discovered during the drug development of 
RXR agonists was LG335 (Figure 2.1a). It is the inactive analogue of a synthetic RXR 
selective activator LG69, an approved drug known as Targretin® (Figure 2.1b)[10, 11].  
Targretin® is used to treat AIDS related Kaposi sarcoma and cutaneous T cell 
lymphoma. LG335 did not bind or activate any RXR subtype[10, 11]. The Doyle group 
constructed RXR variants to reverse the ligand selectivity from its natural ligand 9cRA to 
LG335[9]. Site-directed RXR variants gave a variety of activation profiles with 9cRA 
and LG335. Q275C; I310M; F313I and I310M; F313I; F439L met the criteria for an 
orthogonal receptor; it is activated by LG335, not activated by all-trans retinoic acid, and 


















Figure 2.1    A)  LG335 
B) Targretin® (Bexarotene)  
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To create an orthogonal receptor such that it gives the desired activation profile 
with a ligand, it would helpful if the mutations were designed. In this chapter, it is 
investigated if the mutations in the ligand binding domain have an additive effect on 
function. If the mutations are additive, receptors may be designed for a specific ligand by 
making the appropriate mutations in the ligand binding pocket. Additivity means that if 
one mutation “X” in the LBD has a ∆XEC50 (where EC50 is the concentration of ligand 
producing half maximal activity, and ∆XEC50 is the EC50 of the RXR variant “X” with 
ligand minus the EC50 of the wild-type RXR with ligand), and another mutation in the 
LBD “Y” has a ∆YEC50, then the two mutations together RXR “X+Y” have an additive 
effect, where the experimental ∆XY EC50 will be the same as ∆XEC50 + ∆YEC50 (Figure 
2.2). If the mutations are additive, the plot between the predicted ∆EC50 i.e. ∆XEC50 + 
∆YEC50 versus the experimental ∆EC50 i.e. ∆XY EC50 will have data points falling on the 
straight line, which has a slope of one and zero intercept. Assuming that a straight line 
provides a useful mathematical model of this relationship, regression analysis can be used 
to determine whether this particular straight line model is the best fit for the data.  
 
Results and Discussion 
 
To test if the mutations in the RXR LBD are additive, the RXR variant I310M; 
F313I; F439L was used. Single and double mutants were made, namely I310M, F313I, 
F439L, I310M; F313I, F313I; F439L and I310M; F439L (Figure 2.3, and 2.4). These 
RXR variants were tested in mammalian cell culture with varying 
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∆ X EC50 = Difference of EC50 between “X” and wt RXR  
∆ Y EC50 = Difference of EC50 between “Y” and wt RXR 
∆ XY EC50 = Difference of EC50 between “XY” and wt RXR 






Figure 2.3 Schematic diagram showing ligand bound 
RXR initiating transcription of firefly luciferase. 
Figure 2.2 Concept of additivity.  
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Figure 2.4 Dose response curves:  
A) Wild type RXR and single mutants in response to 9cRA 
B)  RXR double and triple mutants in response to 9cRA          
C) Wild type RXR and single mutants in response to LG335 
















































































concentrations of 9cRA and LG335. The dose response curve of I310M; F313I; F439L, 
single and double mutants are shown in figure 2.4. Based on the response of each variant 
with LG335 and 9cRA, EC50s, and ∆EC50 (variation of EC50 of each variant from wild-
type RXR), the error of ∆EC50 were calculated for each mutant and shown in Table 2.1. 
To test the additivity, a plot was generated between the experimental ∆EC50 of double 
and triple mutant versus their respective predicted ∆EC50 (i.e. experimental ∆EC50 
I310M; F313I versus predicted ∆EC50 i.e. (∆EC50 I310M + ∆EC50 F313I)).  The predicted 
∆EC50 of the double and triple mutants are the sums of the ∆EC50 of the respective single 
mutants. If the mutations have an additive effect on the function, the data points will fall 
on the straight line with an intercept of zero.  
The data points between experimental ∆EC50 and predicted ∆EC50 for the double 
and triple mutants with 9cRA do not fall on the straight line (Figure 2.5). The best fit line 
between the data points has a slope of 0.3000, intercept of 5.0 * 10 -7, and R2 value of 
0.6857 (Table 2.2). The slope of 0.3000 means that with an increase of one unit of 
experimental ∆EC50 the value of predicted ∆EC50 is estimated to increase by an average 
of 0.3000 units. The standard error of the slope is 0.1467 (Table 2.2). R2 value of the line 
is the coefficient of determination that measures the proportion of variation in the 
dependent variable i.e. predicted ∆EC50 that is explained by the independent variable i.e. 
experimental ∆EC50, in the regression model. R2 value is 0.6867; meaning 68% of the 
variation in the predicted ∆EC50 of the mutants can be explained by experimental ∆EC50.  
The standard error of estimate or standard deviation of the line of regression is 3.9*10 -7 
(Table 2.2).  
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Wild type 1.0E-07 4.0E-08 0.0E+00       
F439L 4.0E-09 1.6E-09 -9.6E-08 4.0E-09     
I310M 5.6E-07 2.2E-07 4.6E-07 5.6E-07     
F313I 1.3E-06 5.0E-07 1.2E-06 1.3E-06     
I310M;F313I 2.6E-06 1.1E-06 2.5E-06 2.6E-06 1.6E-06 1.7E-06 
I310M;F439L 6.3E-07 2.5E-07 5.3E-07 6.3E-07 3.7E-07 4.7E-07 
F313I;F439L 1.0E-06 4.0E-07 9.0E-07 1.0E-06 1.1E-06 1.2E-06 
I310M;F313I;F439L 4.0E-06 1.6E-06 3.9E-06 4.0E-06 1.5E-06 1.6E-06 
       
       












Wild type 1.6E-06 6.3E-07 0.0E+00       
F439L 2.0E-06 8.0E-07 4.1E-07 2.0E-06     
I310M 4.0E-06 1.6E-06 2.4E-06 4.0E-06     
F313I 7.9E-07 3.2E-07 -7.9E-07 7.9E-07     
I310M;F313I 3.2E-07 1.3E-07 -1.3E-06 3.2E-07 1.6E-06 3.2E-06 
I310M;F439L 2.0E-06 8.0E-07 4.1E-07 2.0E-06 2.8E-06 4.4E-06 
F313I;F439L 1.3E-07 5.0E-08 -1.5E-06 1.3E-07 -3.8E-07 1.2E-06 
I310M;F313I;F439L 1.6E-07 6.3E-08 -1.4E-06 1.6E-07 2.0E-06 3.6E-06 
Table 2.1 Experimental EC50 and Predicted EC50 of RXR variants in HEK 293T cells 
EC50 is the concentration of ligand producing half maximal activity. Error EC50 is the 
standard deviation of EC50 of each variant from two experiments. ∆ EC50 is the 
difference in EC50 between the variant and wild type RXR. Error ∆ EC50 is the 
propagation of error in ∆ EC50. Values represent averages of experiment repeated twice 











































Figure 2.5  Graph of the predicted ∆ EC50 and the ∆ EC50 of RXR variants I310M; 
F439L, F313I; F439L, I310M; F313I; F439L and I310M; F313I in response to 9cRA. For 
comparison, the line with slope of one and intercept of zero is also shown in red. 
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Table 2.2 Regression analysis of the RXR variants with 9cRA. 
 
SUMMARY OUTPUT      
       
Regression Statistics      
Multiple R 0.828091      
R Square 0.685735      
Adjusted R 
Square 0.528602      
Standard 
Error 3.93E-07      
Observations 4      
       
ANOVA       
  df SS MS F 
Significance 
F  
Regression 1 6.751E-13 6.75E-13 4.364052 0.171908928  
Residual 2 3.0939E-13 1.55E-13    
Total 3 9.8449E-13        
       
  Coefficients 
Standard 
Error t Stat P-value Lower 95% Upper 95% 
Intercept 5.43E-07 3.4853E-07 1.557441 0.259672 -9.567E-07 2.042E-06














One can determine whether a linear relationship exists between the predicted 
∆EC50 and experimental ∆EC50 by testing whether the slope (m) is equal to zero. If this 
hypothesis is rejected, one could conclude that there is evidence of linear relationship. 
 Ho: m = 0 (There is no linear relationship),  
 H1: m ≠ 0 (There is a linear relationship).  
To test the hypothesis a confidence interval is set up to determine whether the 
hypothesized value of slope is equal to zero (m = 0). The confidence interval estimate of 
the slope is calculated with the formula m+ tn-2 Sm = .3066 + 4.302 (0.1467) (m is the 
slope of the line; Sm is the standard error of the slope). Hence with 95% confidence the 
slope lies between -0.3245 < m < 0.9377. The interval includes zero, therefore there is no 
significant linear relationship between the prediction ∆EC50 and experimental ∆EC50 of 
the double and triple mutants. But, when taking into account the propagation of error as 
seen in Figure 2.6 the uncertainty involved with each data point is relatively large. The 
propagation of error analysis suggests we cannot predict the additive behavior unless the 
error is reduced. There are two possible ways we can reduce propagation of error. 
A. If the mutants have a large difference in EC50 from the wild type receptor, 
then the ratio of error would be small.  
B. If the variation between the experiments reduces then the error involved with 
each reading will reduce and hence the propagation in error would reduce.  
The data points between experimental ∆EC50 and predicted ∆EC50 for the double 
and triple mutants with LG335 also do not fall on the straight line (Figure 2.7). The best 
fit line between the data points has a slope of 1.007. The standard error of the slope is 


















y = 0.3066x + 5E-07 























Figure 2.6 Graph of predicted ∆ EC50 and the ∆ EC50 of RXR variants I310M; 
F439L, F313I; F439L, I310M; F313I and I310M; F313I; F439L incorporated with 
the error of propagation, in response to 9cRA. For comparison, the line with slope of 
one and intercept of zero is also shown in red. 
 42
intercept of the best fit line is 2*10-6 and the R2 value is 0.4478 (Table 2.3).  R2 value is 
the coefficient of determination that measures the proportion of variation in the 
dependent variable (predicted ∆EC50) that is explained by the independent variable 
(experimental ∆EC50). In this regression model R2 value is 0.4478; meaning 44% of the 
variation in the predicted ∆EC50 of the mutants can be explained by experimental ∆EC50.  
The standard error of estimate or standard deviation of the line of regression is 1.2*10-
06(Table 2.3).  
One can determine whether a linear relationship between the predicted ∆EC50 and 
experimental ∆EC50 exists by testing whether the slope (m) is equal to zero. If this 
hypothesis is rejected, one could conclude that there is evidence of linear relationship. 
 Ho:  m = 0 (There is no linear relationship),  
 H1: m ≠ 0 (There is a linear relationship).  
To test the hypothesis a confidence interval is set up to determine whether the 
hypothesized value (m = 0). With 95% confidence the slope lies between -2.395 < m < 
0.409. The interval includes zero, therefore these is no significant linear relationship 
between the prediction ∆EC50 and experimental ∆EC50 of the double and triple mutants. 
Also, when taking into account the propagation of error as seen in Figure 2.8 the 
uncertainty involved is relatively large. The propagation of error analysis suggests that 
the mutations do not have an additive function within the uncertainties of the EC50’s.  
 
Materials and Methods 
 



























y = x 
R2 = 1 
y = 1.0069x + 2E-06
























Figure 2.7 Graph of predicted ∆ EC50 and the ∆ EC50 of RXR variants I310M; F439L, 
F313I; F439L, I310M; F313I and I310M; F313I; F439L in response to LG335. For 
comparison, the line with slope of one and intercept of zero is also shown in red. 
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SUMMARY OUTPUT      
       
Regression Statistics      
Multiple R 0.669154      
R Square 0.447767      
Adjusted R 
Square 0.171651      
Standard 
Error 1.2345E-06      
Observations 4      
       
ANOVA       
  df SS MS F 
Significance 
F  
Regression 1 2.471E-12 2.47E-12 1.6216 0.33084  
Residual 2 3.047E-12 1.52E-12    
Total 3 5.519E-12        
       
  Coefficients 
Standard 
Error t Stat P-value Lower 95% Upper 95% 
Intercept 2.4544E-06 9.6365E-07 2.546956 0.12573 -1.691E-06 6.600E-06





































y = 1.0069x + 2E-06
R2 = 0.4478
y = x 
























Figure 2.8 Graph of predicted ∆ EC50 and the ∆ EC50 of RXR variants I310M; F439L, 
F313I; F439L, I310M; F313I and I310M; F313I; F439L in response to LG335 with 
propagation of error incorporated. For comparison, the line with slope of one and 
intercept of zero is also shown in red. 
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Mutants RXR I310M, RXR F313I, RXR F439L, RXR I310M; F313I, RXR 
F313I; F439L and RXR I310M; F439L and RXR I310M; F313I; F439L were made via 
site directed PCR [9].   
 
Cell culture and transfection 
 
Day prior to the transfection, CV-1 cells were plated with the density of 25000 
cells per well in 48-well culture plates. Transfection was performed using lipofectamine 
cationic lipid (Invitrogen). Each well contained 20 ng of the expression plasmid (RXR 
variant), 40 ng of pLucCRBPII and pCMXβgal. Eight hours after transfection, the media 
was removed and replaced with DMEM+10% charcoal resin stripped calf bovine serum 
containing appropriate concentration of ligand. The cells  
were allowed to incubate with ligand for thirty six hours before harvesting. Cell extracts 
were assayed for luminescence using a luminometer. Activity is reporter in relative light 
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Small molecules that modulate the activity of biological signaling such as 
agonists and antagonists for receptors are a powerful tool for studying protein function. 
To date, many receptors have being engineered to respond to unnatural or synthetic 
ligand.  One of the pioneer works in engineering proteins to accept an unnatural substrate 
by altering electrostatic interaction was done by Hwang and Miller, where specificity of 
elongation factor Tu, a GTPase, was altered to an XTPase by a single mutation of 
aspartate 138 to an aspargine[1]. This work started the era of protein engineering.  
Another earlier example of protein engineering was engineering ĸ-opioid, a seven 
transmembrane receptor to respond only to a synthetic ligand[2]. This change was done 
by swapping an extracellular loop from γ-opioid receptor Ro1 and by making the point 
mutation glutamic acid 297 to glutamine in the first external loop[2]. Shokat and 
coworkers used a structure-based design to engineer the ATP-binding site of v-Src, a 
protein kinase to uniquely accept N6 ATP analogs by mutating the bulky residue in the 
active site, isoleucine 338, to an alanine or a glycine[3, 4]. Other notable work was done 
by Smith and coworkers on an orthogonal human carboxypeptidase A1 (hCPA1). They 
engineered hCPA1, such that the enzyme hydrolyzed an unnatural substrate methotrexate 
(MTX) prodrugs[5]. This change was achieved by synthesizing derivatives of MTX-Phe 
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with bulky substituents at the positions 2 and 3 of MTX and making mutants of hCPA1 at 
threonine 268 to have smaller amino acids such as glycine or alanine[5].  
 Creating a matched pair of a synthetic ligand and an engineered receptor that are 
orthogonal to the wild type interaction is called an orthogonal ligand receptor pair 
(OLRP)[6]. OLRP can provide insight in structural specificity between various ligand-
receptor pairs, and to understand cellular and metabolic pathways.  OLRPs offer the 
ability to control transcription by behaving as a small molecule dependent molecular 
switch. These molecular switches can be used for practical applications such as gene 
therapy by regulating the expression of target gene[7]. The molecular switches or OLRP 
may behave as a rheostat or as an on/off switch depending on their response to the ligand. 
To utilize these switches for gene therapy, genes for orthogonal receptor or molecular 
switch would be delivered along with the target gene (Figure 1.2). The molecular switch 
once expressed in the cells would bind to its unique binding site in the promoter region of 
the target gene. In the presence of ligand, the receptor will be activated and express the 
downstream target gene. Depending on the dosage of the ligand and the activation level 
of the receptor the target gene will be expressed. OLRP can also be utilized to reveal the 
function for thousands of gene that were discovered in the genome project with unknown 
function.  
Nuclear receptors (NR) are good candidates for creating OLRPs. NR’s are a 
super-family of ligand activated transcription factors that are composed of steroids and 
non steroidal receptors which control a broad range of physiological processes. These 
proteins contain an evolutionarily conserved DNA binding domain (DBD) and ligand-
binding domain (LBD). The LBD binds to a small molecule and the DBD binds to a 
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DNA sequence called response element (RE). NRs are modular proteins, such that 
alterations within the ligand binding domain will not disrupt the DNA binding domain 
and vice versa. The proteins are attractive targets for constructing novel ligand receptor 
pairs and controlling transcription for two reasons: 1) Small molecule derivatives are 
available and can be synthesized to bind and activate these receptors. 2) NR response 
elements can be introduced into the promoter regions of any gene and hence enabling the 
regulation of gene expression.  
Retinoid X receptor (RXR) is a nuclear receptor that belongs to the class of 
retinoid receptors[8]. Retinoid receptors contain of retinoic acid receptors (RAR) that 
bind and respond to all-trans retinoic acid, and the RXR is activated by the retinoic acid 
stereoisomer 9-cis retinoic acid (Figure 1.3)[9]. RXR forms a homodimer with itself 
(Figure 1.5) and heterodimers with other nuclear receptors such as thyroid hormone, 
vitamin D receptor, peroxisome proliferator-activated receptor and RAR[10, 11]. These 
heterodimers have distinct response element specificities to mediate the hormonal 
response to target gene transcription. Response elements are comprised of direct repeats 
(DRs) of a common half-site with the spacing between repeats which is a critical in 
mediating specificity.  RARs activate preferentially through DRs spaced by two or five 
nucleotides, whereas RXR homodimers activate preferentially through DRs spaced by 
one nucleotide[12, 13]. Heterodimeric complexes of RXR-RAR have shown to mediate 
transcription via response elements composed of palindromes as well as inverted 
palindromes. The dimerization interface has been identified within the DBD of the 
receptors that promotes DNA binding[14, 15]. But there is additional dimerization 
interface within the LBD of RAR, and RXR[16-18]. A 40-amino acid region in RXR 
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(amino acid 389-429) and RAR constitute critical regions in their heterodimerization and 
efficient DNA binding[19, 20]. 
 Koh and colleagues at the University of Delware have rationally designed retinoid 
acid receptor, a member of NR superfamily, to respond to novel synthetic ligands and 
selectively activate genes [7]. Crystal structure of all trans retinoic acid (atRA) with RAR  
was used to design a receptor ligand pair. Two residues serine 289 and arginine 278, were 
shown to interact with carboxylic acid moiety of atRA, and these residues were critical 
for electrostatics and for ligand binding. Mutation of one or both of these residues to 
glycine or negatively charged residues such as aspartic or glutamic acid results in RAR 
activation by neutral and basic charged analogs of RA, and not its natural ligand, 
negatively charged atRA. Koh’s group also created an orthogonal estrogen receptor-
ligand pair by polar group exchange[8]. They changed the covalent connectivity of polar 
groups involved in an intra-molecular protein salt-bridge. The crystal structure of the 
human estrogen receptor (ER) and estradiol shows that the 3-hydroxyl of estrogen is held 
via hydrogen bonds to an intra-molecular protein salt-bridge formed by glutamine (G) 
353 and arginine (A) 394 [9]. 3-hydroxyl group of estradiol and G353 have been shown 
to be important for the selectivity [10, 11]. They substituted the carboxylate of LG353 
with alanine, and the variant ER G353A, lacks a carboxyl group critical for high-affinity 
binding of estradiol. This variant is able to activate by a carboxylate-functionalized 
estrogen analog, ES8 at nano molar concentration, whereas wild type ER is not. Ligand 
ES8 activates ER G353A at concentrations that do not activate the wild type ER. 
Previously, Doyle and coworkers in an attempt to create OLRP’s, constructed a 
variety of RXR variants to respond to various synthetic ligands[21, 22]. One of the 
 
52
orthogonal ligand LG335, an inactive analogue of a synthetic RXR selective activator 
LG69 also known as Targretin® did not bind or activate any wild type RXR subtype 
(Figure 2.1) [23, 24]. The Doyle group constructed RXR variants to reverse the ligand 
selectivity from its natural ligand 9cRA to LG335 via site directed mutagenesis. They 
converted the RXR residues 3.9 Å of any ligand carbon atom to their RAR counterparts, 
with the reasoning that the changes will alter the specificity for ligand without major 
structural modification of RXR. Three residues within the 3.9 Å of the oxygen atoms of 
the carboxylate were untouched as LG335 also contain the carboxylic group. RXR 
variants gave a variety of activation profiles with 9cRA and LG335. RXR Q275C; 
I310M; F313I (QCIMFI) was activated by LG335 and slightly activated by 9cRA (Figure 
3.1). 
Here the RXR variant QCIMFI was modified to create a fully orthogonal receptor 
and behave as a molecular switch to control transcription.  For the engineered ligand 
receptor pair to behave like a molecular switch and aid in gene therapy it should meet the 
following criteria (Figure 3.2) 
1. The DNA binding domain should only recognize a unique binding site 
2. The ligand binding domain should preferentially bind to a synthetic small 
molecule and not any endogenous ligand. 
3. The receptor should not dimerize with wild type RXR or similar protein such as 
RAR  
To engineer a fully OLRP that fulfils all the above criteria’s, the DBD of RXR 




Figure 3.1 Dose response curves of wild type RXR and RXR variant 
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Figure 3.2 Experimental setup to show the GR Q275C; I310M; F313I and 
LG335 are orthogonal. Tested for interactions between 1) Wild type receptor 
and LG335. 2) GR variant and ligand (LG335, 9cRA or atRA) 3) Wild type 
RXR and RAR with Gal4 response element. 4)  GR variant and Gal4 RE and 

























binding domain (Gal4 DBD). The variant Gal4 DBD- RXR QCIMFI (GR QCIMFI) 
would solve two purposes; it would prevent activation of any RXR responsive genes i.e. 
genes controlled by RXR RE and the wild type RXR will not bind and activate Gal4 RE 
driven target gene.  
 
Results and Discussion 
 
 Response element orthogonality 
 
 To achieve target specificity and to eliminate the possibility of simultaneous 
activation of any endogenous RXR responsive genes the DNA binding domain of the 
RXR variant was replaced by Gal4 DBD. Gal4 DBD is a yeast transcription factor that 
recognizes a unique DNA sequence of 17 base pairs called Gal4 RE. Gal4 activated 
genes are not known to exist in mammalian cells, hence this regulator should be specific 
for the target gene of interest. In theory, in the presence of LG335 the GR variant should 
only activate the target gene containing the Gal4 binding sites. HEK293T cells were co-
transfected with plasmids expressing GR variant QCIMFI (pCMXGR QCIMFI), wild 
type RXR (pCMX RXR), four repeats of Gal4 RE driven Renilla luciferase (p17*4Tata 
Rluc) and RXR RE driven firefly luciferase (pLucCRBPII). In the presence of LG335, 
the GR variant was activated and expressed Gal4 RE driven Renilla luciferase but did not 
bind to RXR RE and hence did not activate RXR RE driven firefly luciferase (Figure 
3.3). In the presence of 9cRA, wild type RXR was activated and expressed RXR RE 
controlled firefly luciferase but did not bind Gal4 RE or express Renilla luciferase 
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(Figure 3.3). This data shows that Gal4 DBD recognizes only the Gal4 RE not the RXR 
RE, and RXR does not recognize Gal4 RE. To further examine the specificity of Gal4 
DBD and Gal4 RE, it was tested with retinoid acid receptor and RAR response element.   
RAR belongs to the same family of retinoid receptors as the RXR. It is 
structurally similar to RXR and shares the common modular domains that can be 
interchanged without the loss of function [25, 26]. RAR and RXR form heterodimers that 
bind a specific DNA sequence called the RAR response element [13, 27].  HEK293T 
cells were co-transfected with plasmids expressing the GR variant QCIMFI, wild type 
RXR, Gal4 RE driven Renilla luciferase and RAR RE driven firefly luciferase. The result 
shows that in the presence of LG335, GR variant did not bind RARE and activate firefly 
luciferase (Figure 3.4). In the presence of atRA, wild type RAR did not bind and activate 
Gal4 RE controlled firefly luciferase (Figure 3.4). This result confirms the target 
specificity of the GR variant with Gal4 RE driven target gene and that RAR or RXR does 
not recognize Gal4 RE.  This result confirms the target specificity of the GR variant with 
Gal4 RE driven target gene.  
 
 
 Testing for ligand orthogonality   
 
 Altering the ligand selectivity requires changing the binding pocket residues of 
the LBD such that it is activated only in the presence of the synthetic drug. Upon binding 
the ligand, the LBD of the nuclear receptor undergoes a conformational change that leads 
















































Figure 3.3 Activation profile of wild type RXR and GR Q275C; I310M; 
F313M in response to 9cRA and LG335, respectively. Two different reporter 
plasmids are employed containing the Gal4 response element driven Renilla 
































































Figure 3.4 Activation profile of wild type RAR and GR Q275C; I310M; 
F313M in response to atRA and LG335, respectively. Two different reporter 
plasmids are employed containing the Gal4 response element driven Renilla 
luciferase or the RAR response element driven firefly luciferase. 
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the LBD plays a central role in controlling the ligand-induced conformational change 
and forms a part of the receptor/co-activator interface. This aspect of changing the RXR 
LBD 
residues was previously performed by Doyle and coworkers in CV-1 cell line (green 
monkey kidney cells)[22]. Three residues Q275, I310 and F313 that are within the 4.4 Å 
of the bound 9cRA were mutated to cysteine, methionine and isoleucine respectively.   
These mutations were made so that the RXR variant would be preferentially activated by 
LG335 and not its natural ligand, 9cRA (Figure 3.1). Mutations at I310 and F313 would 
provide space for the propyl group of LG335. The RXR DNA binding domain of this 
variant was replaced with Gal4 DNA binding domain as explained in the previous section 
(GR variant). HEK293T cells were transfected with plasmids encoding for the wild-type 
RXR, GR QCIMFI, Gal4RE linked renilla luciferase gene and RXR RE driven firefly 
luciferase gene respectively. The GR QCIMFI had the same response with the ligands in 
HEK293T cells as in CV-1 cells (Figure 3.5). The mutation caused an altered specificity 
with little activation in response to 9cRA and dose response with LG335 (Figure 3.5). 
The EC50 of GR QCIMFI with LG335 was 50 nM and with 9cRA was 100 nM. On the 
other hand, the wild type RXR was not activated with LG335.  
To further examine ligand orthogonality, the GR variant was tested with atRA and 
wild type RAR was tested with LG335. RAR shares 27% sequence identity with RXR in 
their LBD. If the GR variant is orthogonal to the ligand atRA, ligand orthogonality would 
be reinforced. In the presence of atRA, GR QCIMFI was not activated and did not 
express Renilla luciferase also wild type RAR did not express RAR RE driven firefly 






















































Figure 3.6 Activation profile of wild type RXR and GR Q275C; I310M; F313I 
in response to 9cRA and LG335.  
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in the presence of LG335 (Figure 3.6). This data shows that GR QCIMFI was activated 
by LG335, slightly activated by 9cRA and not activated by atRA. Also, RXR and RAR 
were not activated by the orthogonal ligand LG335. 
To explore which mutation or combination of mutations in the LBD of RXR were 
critical for the ligand based orthogonal behavior, the variant RXR was characterized. 
Single mutants of RXR Q275C, I313M and F313I containing the RXR DBD were 
constructed and co-transfected in mammalian cell culture[22]. The result was analyzed 
using a reporter plasmid containing the RXR RE linked to firefly luciferase. The 
transfection result from the RXR variants Q275C, I310M, F313I individually and their 
combination gave a variety of EC50 with LG335 and 9cRA ranging from .1 µM to 1 µM 
(Figure 3.7).  RXR variant Q275C had a low activation level with both 9cRA and LG335, 
F313I was activated with both 9cRA and LG335, and I310M had low activation with 
LG335 and slightly activated with 9cRA. Hence all the single mutations were not 
orthogonal. In combination of two single mutant’s co-transfected, Q275C and I310M 
together was slightly activation with LG335, Q275C and F313I was activated by both 
9cRA and LG335 to equal levels. RXR variant I310M and F313I together were activated 
by LG335 but the EC50 was 500 nM, which was higher then the triple mutant. In addition, 
with 9cRA this mutant was slightly activated. Hence all the three mutations are required 
for RXR variant to behave as an OLRP.  
 
Dimerization Orthogonality  
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Figure 3.6 Activation profile of wild type RAR and GR Q275C; I310M; F313I 
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Figure 3.7 Dose response curves of RXR single, double and triple variant with 





dimerization interface of RXR such that it does not dimerize with other proteins.  RXR is 
a universal partner in the nuclear receptor family. It forms heterodimers with a variety of  
receptors including itself, RAR, vitamin D receptor, thyroid receptor and peroxisome 
proliferator activated receptor[28-30]. The DBD of RXR and its heterodimeric partners 
do not interact in the absence of response elements[14, 31]. Dimerization is mediated 
primarily by the interacting surface of the LBD on the receptor and is believed to 
stabilize the complex and promote the recognition of DNA[19].   
Though the dimerization interface in the LBD was not modified, it was examined 
whether replacing the RXR DBD with Gal4 DBD would abolish GR variants 
dimerization with its partners. The GR variant is most similar to wild type RXR and RAR 
and was tested with these receptors for dimerization. It was observed that the HEK293T 
cells transfected with both GR variant and wild type RXR or RAR had a similar Renilla 
luciferase activity as observed from the cells containing the GR variant alone (Figure 
3.8). This result implies that in the presence of LG335, the wild type RXR or RAR are 
not interacting with the GR variant to affect the expression of Gal4 RE controlled Renilla 
luciferase. If dimerization would have occurred, a decrease in Renilla luciferase activity 
would be observed as the RXR LBD-RXR DBD and RXR LBD-Gal4 DBD dimer would 
not be able to bind Gal4 RE with as much affinity as RXR LBD - Gal4 DBD homodimer. 
Also, in the presence of atRA, firefly luciferase activity from the cells transfected with 
both wild type RAR and GR variant was the same as firefly luciferase activity from the 
cells transfected with RAR alone (Figure 3.8). This data implies that the RAR and GR 



































Figure 3.8 Graphs showing dimerization orthogonality between GR QCIMFI and 
wild type RXR and RAR 
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The data from response element, ligand and dimerization orthogonality imply that 
by generating three mutations in the LBD and replacing the RXR DBD with Gal4 DBD 
alters the response element, ligand specificity and abolish the dimerization between the 




 In conclusion a fully orthogonal ligand receptor pair was constructed using 
retinoid X receptor and synthetic ligand LG335. The three criteria for orthogonality were  
1 The DNA binding domain of the orthogonal ligand receptor pair should only 
recognize a unique binding site. 
2  The ligand binding domain should preferentially bind to a synthetic small 
molecule and not any endogenous ligand. 
3 The receptor should not dimerize with other nuclear receptor such as wild type 
retinoid X receptor or retinoic acid receptor. 
The receptor was made target specific by replacing the RXR DNA binding 
domain with a Gal4 DBD and introducing a Gal4 response element before the target 
gene. Three mutations Q275C; I310M; F313I (QCIMFI) were made in the ligand binding 
domain to alter the ligand specificity from 9cRA to LG335[22]. It was determined that 
not any of these mutations alone were enough to cause ligand orthogonality. Switching 
RXR DBD to Gal4 DBD also prevents the variant from dimerizing with other nuclear 
receptors such as wild type RAR and RXR. This variant GR (QCIMFI) qualifies to be an 
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orthogonal ligand receptor pair and can be used for practical applications such as a 
molecular switch to regulate gene expression. 
 




9-cis retinoic acid (MW=304.44g/mol) and all trans retinoic acid was purchased 
from ICN Biomedicals. LG335 was synthesized  by Dr Lauren Schwimmer [32] 
 
  Expression and reporter plasmids  
 
Plasmid were obtained from various sources, pCMX-hRXR was a gift from Dr 
Ronald Evans (Salk institute for biological studies, La Jolla, CA) [33], pCMX-hRXR 
(Q275C; I310M; F313I) was previously constructed by Dr Donald Doyle [22], To 
construct pCMXGR QCIMFI, PCR amplified fragment of  Gal4 DBD fused to RXR 
LBD Q275C; I310M; F313I was cloned from pGBD RXR Q275C; I310M; F313I into 
pCMX-hRXR using KpnI and PstI. pCMXGR wt was constructed from pGBD RXR wt 
in the same way as pCMXGR QCIMFI. p17*4 Tata Luc expressing firefly luciferase 
under the control of four Gal4RE was a kind gift from Dr Sofia Tsai (Baylor college, 
Houston, TX)[34, 35], p17*4 Tata Hrl was made by replacing firefly luciferase from 
p17*4 TataLuc with NotI and SacII restriction site and inserting Renilla luciferase gene 
from pHRL (Clonetech), pCMXβGal [21], pBRE-Luc, pLucCRBPII expressing firefly 
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luciferase under the control of RXR RE was made by site-directed mutagenesis from 
pLucMCS (Stratagene, USA). Site-directed primers were designed to incorporate a 
CRBPII response element in the multiple cloning site.  All the plasmids were sequencing 
confirmed. 
 
Mammalian Cell Culture  
 
HEK293T cells were cultured in DMEM supplemented with 10% calf bovine 
serum. Twenty four hours before transfection, HEK293T cells were plated with the 
density of 25000 cells per well in 48-well culture plates. After the cells were 75% 
confluent it was transfected with pCMX-hRXR (20-40ng), pLucCRBPII (40-80ng) and 
pCMXβGal (40-80ng) or pCMXGR QCIMFI(20-40ng), p17*4 Tata Hrl (40-80ng), and 
pCMXβGal (40-80ng) or all of them together. The transfection reagent used was either 
Lipofectamine® or Lipofectamine 2000® cationic lipid (Gibco BRL/Life technologies).  
Ten  to twelve hrs after transfection, the media was removed and replaced with 
DMEM+10% charcoal resin stripped calf bovine serum containing appropriate 
concentration of ligand. The cells were allowed to incubate with ligand for twenty four- 
thirty six hours before harvesting. Cell extracts were assayed for firefly luciferase, 
Renilla luciferase and β-galactosidase activity using the luminometer and plate reader. 
Activity is reporter in relative light units (RLU) determined as the ratio of the firefly or 
Renilla luminescence divided by β-gal reading (control). 
 
Preparation of Reagents 
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Mango lysis buffer For a 96 well plate, the mango lysis buffer consist of mango 
lysis base buffer (10 mL at 4 °C), 0.1 M EGTA (425 µL), 0.5 M MgCl2 (170 µL), 1.0 M 
DTT (10.6 µL), and 250 mM PMSF (17 µL). 
Firefly luciferin For a 96 well plate, the firefly luciferase assay buffer consist of 
10X luciferin stock (1.35 mL) and 0.1 M KPO4 at pH 7.8 (12.15 mL). 
Firefly luciferase assay buffer For a 96 well plate, the firefly luciferase assay 
buffer consist of water (8.2 mL), 1.0 M KPO4 (1 mL), 0.5 M MgCl2 (430 µL), and 0.1 M 
ATP (370 µL). 
Renilla luciferase assay buffer 7.5 mM Na4PPi, 200 mM Na2SO4, 10mM CDTA 
and 1 µM coelentrazine  
β-galactosidase assay buffer: For a 96 well plate, β-galactosidase buffer (10 mL), 




After thirty - forty eight hours of transfection the cells are assayed for firefly 
luciferase, Renilla luciferase and β-galactosidase activity using the luminometer and plate 
reader respectively.  The media from the 48 well plate is aspirated and the cells are lysed 
using mango lysis buffer (100 µL/per well).  The plate was gently shaken for five minutes 
and the cell extract was transferred to a 96 well plate, 100 µl cell extract per well. From 
this 96 well master plate, cell extract is transferred into three 96 well plates, 20 µl of cell 
lysate per well for firefly luminescence assay, 20 µl of cell lysate per well for Renilla 
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Gene therapy involves introducing a functional gene that produces a therapeutic 
protein to treat or prevent diseases. One of the challenges of gene therapy is controlling the 
production of the therapeutic protein. Over or under-production of the therapeutic protein can 
cause side effects, hence it is important to regulate therapeutic gene expression. Initial 
attempts to control gene expression have used endogenous cellular elements such as 
promoter and enhancer that respond to exogenous signals. Some of these regulatory systems 
are temperature responsive system[1, 2], heavy metal ion based gene regulation[3], and 
oxygen tension driven system[4].  However, these approaches have had limitations due to a 
high basal expression in the uninduced state, because of interference due to inducing 
condition or low regulation performance i.e. low induction ratio. Currently the most widely 
used method to control gene expression and  produce relatively high levels of the therapeutic 
protein is ligand inducible gene expression.  Ligand-dependent inducible systems are usually 
based on two components:  1) a chimeric transcription factor containing a DNA-binding 
domain (DBD) fused to a ligand binding domain (LBD), where the DBD does not bind 
endogenous sequences, and the LBD interacts only with its unnatural ligand; 2) an artificial 
promoter consisting of multimeric-binding sites for the DBD followed by a minimal 
promoter and the target gene.  
In the presence of the ligand the transcription factor is recruited to the promoter and 
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 expresses the target gene downstream of this promoter. Neither the chimeric transcription 
factor nor the ligand should interact with any endogenous protein or endogenous small 
molecule, in other words they need to be orthogonal to cell function (as defined in chapter 3). 
A good inducible system is one that provides the ability to control protein levels 
quantitatively, in a timely manner, over an extended period of time without eliciting an 
immune response. To be used in human gene therapy, the molecular switch should meet the 
following criteria:  
(1) Should be an ON switch i.e. the ligand should activate rather than repress 
transcription (OFF-switch). This is because an OFF-switch requires a prolonged exposure to 
the drug and induction kinetics are determined by the rate of drug clearance. 
 (2) The ligand and the molecular switch should be target specific and not interfere 
with endogenous metabolic pathways. 
 (3) The ligand should be orally bioavailable, be able to penetrate the target tissues 
and have a compatible metabolic profile over extended period of therapeutic use. 
 (4) Target gene expression should correlate with the dose of the ligand. 
(5) The system should have low basal activity i.e. be inactive in the absence of the 
ligand but strongly stimulated by ligand administration, hence high fold activation.  
(6) The molecular switch should not elicit an immune response in humans. 
Here a transcription based molecular switch is developed using an orthogonal ligand 
receptor pair: LG335 and an RXR variant. Presently, there are three widely used inducible 
systems that are similar to the molecular switch proposed and each of them has advantages 
and disadvantages. 1) The progesterone receptor (PR) inducible system regulates gene 
expression using mifepristrone (RU486) and PR mutant, known as GeneSwitch® [5, 6]. The 
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advantage of this system is that it comprises of human protein and does not have an immune 
response, strongly induces transcription and responds to .1 nM concentrations of 
mifepristrone. But the performance of this system remains poor with a high level of basal 
activity in the absence of the inducer, resulting in a low induction level [7]. Mifepristrone is 
used in several countries as a treatment to terminate pregnancy. Though mifepristrone 
stimulates GeneSwitch® maximally by oral doses of at least one order of magnitude lower 
than those required to induce abortion (about 200–600 mg), it may also affect the ovarian 
cycle and exert a contraceptive activity. 2) The tetracycline (Tet) based inducible system is 
well characterized and widely used, however the proteins may be immunogenic because 
there are derived from bacteria. The Tet-system is apparently not immunogenic in several 
mouse strains, however recent studies indicate that intramuscularly delivered Tet-ON 
activators may elicit a cellular and humoral response in non-human primates[8, 9].  3) The 
ecdysone receptor dependent gene regulatory system is based on a heterodimer between 
insect steroid hormone receptor (EcR) and RXR known as RheoSwitch®[10]. This system 
has very a low level of basal expression and hence high fold induction (>10000) [11, 12]. 
However, it requires the over expression of two genes (EcR and RXR) simultaneously which 
complicates its use in viral delivery systems. RXR is a reluctant dimer of EcR and efficient 
transactivation can only be achieved by overexpressing RXR in the target cells. This poses a 
safety concern as RXR is involved in many metabolic pathways. A recent finding has shown 
that RXR overexpression causes dilated cardiomyopathy in mice[13]. Also, the insect 
hormone and their derivates may not be approved for human therapeutic use.  
Here, an attempt is made to create a molecular switch that requires over-expression of 
only one protein, produces a high induction level at low concentrations of a non-toxic 
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synthetic ligand. Previously a molecular switch was created using an orthogonal ligand 
receptor pair; a synthetic ligand LG335 and a RXR variant (Q275C; I310M; F313I) 
containing Gal4 DBD (described in chapter 3). This RXR variant is an ON switch, i.e. it 
turns on the transcription of the target gene in the presence of the ligand LG335. It is 
orthogonal to the endogenous proteins such as wild type RXR and RAR and is target specific 
i.e. the Gal4 DBD recognizes its binding site, Gal4 RE, and transcribes only Gal4 RE driven 
target genes. Also, the variant does not recognize the RXR RE and hence do not interfere 
with RXR responsive gene.  The mutations in the variant Q275C; I310M; F313I altered 
ligand selectivity from the natural ligand 9cRA to LG335. The EC50 for LG335 is 50 nM and 
the induction ratio is 8 fold.   
To design a more sensitive molecular switch that has a lower EC50 and high fold 
induction with LG335, structure-based approach was applied to generate libraries of RXR 
variants[14]. A general method was developed for docking ligands into the binding pocket of 
the RXRα LBD crystal structure which was obtained from the protein databank. LG335 was 
manually placed in the binding site of RXR and the atoms of LG335 were superimposed onto 
the atoms of the crystallographic 9cRA. The binding pocket of RXR is hydrophobic and the 
majority of substitutions were made on the basis of size, charge or hydrophobicity. The 
randomized amino acids were chosen on the basis of their proximity to the bound 9cRA as 
observed in the crystal structure. Mutations were made at six positions (I268, A271, A272, 
I310, F313, and L436). The first three positions had four possible mutations (leucine (L), 
valine (V), alanine(A) and proline (P)) and the other three positions had eight possible amino 
acids leucine (L), isoleucine (I), valine (V), phenylalanine (F), methionine (M) , serine (S), 
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alanine (A) and threonine (T)). The combination of six positions and number of possible 
amino acids kept the library size to 32,768 amino acid combinations.   
To discover the functional variants within the libraries, a genetic selection assay 
method called chemical complementation. Chemical complementation is a method in which 
the survival of the yeast is dependent on a functional variant and a small molecule. The 
engineered receptor are fused to the Gal4 DBD and transformed into yeast with the 
appropriate coactivator ACTR-Gal4 activation domain (Figure 4.1). Yeast transformants 
were plated on adenine selective media with a certain concentration of LG335. The variants 
that are able to bind and activate the receptor will express ADE2 gene allowing the yeast 
cells to survive on the selective media. The variants that bind LG335 and not 9cRA were 
rescued from the yeast and sequenced. Table 4.1 summarizes the transcriptional activation 
profiles of all twelve variants in response to both 9cRA and LG335 compared to wild-type 
RXR.  
The library produced ~380,000 transformants designed for the synthetic retinoid-like 
compound LG335.  In yeast, wild-type RXR has an EC50 of 500 nM with 9cRA and an EC50 
>10 µM LG335. The library produced ligand-receptor pairs with LG335 that have a variety  
of EC50s (40nM to > 2 µM) and activation levels (10% to 80% of wild-type RXR with. 
9cRA). Some of the variants behaved as switches and some as rheostats, they had wild-type 
levels of activation (> 50% efficacy) and some were low (<25%) as shown in figure 4.1 
 
Results and Discussion 
 


























Figure 4.1 Chemical complementation in yeast:  Yeast cells 
transformed with RXR variants fused to the Gal4 DBD and the 
appropriate coactivator ACTR-Gal4 activation domain. Yeast cells 
containing the RXR variants that are activated by the ligand express 











Variant EC50 Eff EC50 Eff EC50 Eff EC50 Eff
(nM) (%) (nM) (%) (nM) (%) (nM) (%)
WT 500 100 220 100 >10,000 10 300 10
I268A;I310A;F313A;L436F >10,000 0 >10,000 0 220 70 30 50
I268V;A272V;I310L;F313M >10,000 10 >1600 30 40 60 1 30
I268A;I310S;F313V;L436F >10,000 10 470 60
I268A;I310S;F313A;L436F >10,000 0 >10,000 0 430 50 690 20
I268V;A272V;I310M;F313S;L436M >10,000 10 >10,000 0 680 30 180 30
I268A;A272V;I310A;F313A;L436F >10,000 0 530 30
I268L;A271V;I310L;F313L >10,000 0 530 20
I268A;I310M;F313A;L436T >10,000 0 >10,000 0 610 10 140 20
I268V;A271V;I310L;F313V >10,000 0 650 10
I268L;I310V;F313I >10,000 0 >2000 10
I268L;I310M;F313V >10,000 20 610 20






Figure 4.2 Schematic diagram 
showing LG335 bound RXR variant      
initiating transcription of firefly 
luciferase
Table 4.1 EC50 and Efficacy (Eff) of the twelve RXR variants in response to 9cRA and LG335 
in yeast and mammalian (HEK293T) cells. 
EC50, is the concentration of ligand producing half maximal activity.  
Eff, maximum increase in activation relative to the increase in activation of wild type with 10 




With the data obtained from the RXR  library, five RXR variants [I268A; I310A; 
F313A; L436F, I268V; A272V; I310L; F313M, I268A; I310S; F313A; L436F, I268V; 
A272V; I310M; F313S; L436M, and I268A; I310M; F313A; L436T] containing the RXR 
DBD was cloned in mammalian expression vectors. Plasmids encoding for the RXR variants 
and the RXR RE driven firefly luciferase were transfected in HEK293T cells (Figure 4.2). 
The activation profile of these variants in response to 9cRA and LG335 is shown in figure 
4.3. Among the five RXR variants, two of them I268A; I310M; F313A; L436T, I268A; 
I310S; F313A; L436F have low activation level (similar to the activity of wild type RXR 
with LG335), relatively high EC50 (i.e. the concentration of ligand producing half maximal 
activity) of 140 nM and 690 nM respectively and efficacy of 20% (Efficacy is the maximum 
increase in activation relative to the increase in activation of wild type RXR with 10µM 
9cRA) (Figure 4.1, 4.3). The other three RXR variants I268V; A272V; I310L; F313M, 
I268A; I310A; F313A; L436F and I268V; A272V; I310M; F313S; L436M were activated by 
LG335 to a higher level then wild type RXR, they have lower EC50 for LG335of 1 nM, 30 
nM, and 180 nM respectively and their EC50 for 9cRA of  > 1 µM. The efficacy of the 
variants was 30%, 50% and 30% respectively. The RXR variant I268V; A272V; I310L; 
F313M with 1 nM EC50 for LG335 was 25-fold lower than the previous best orthogonal 
receptor RXR Q275C; I310M; F313I [15]. It behaved more like a switch rather than a 
rheostat.     
 
Converting the RXR variants into GR variants 
 











































 Figure 4.3. Activation profile of the RXR variants in response to 9cRA (a) and LG335 
(b) in HEK293T cells.  with wild-type RXR (wt RXR, filled circle), 
I268A;I310S;F313A;L436F (horizontal line), I268V;A272V;I310M;F313S;L436M 
(downward-pointing triangle), I268A;I310M;F313A;L436T (yellow square), 
I268V;A272V;I310L;F313M (upright pointing triangle), or I268A;I310A;F313A;L436F 
(pink circle).The 10-12 M point is 0 M ligand concentration. RLU, relative light units.  
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potential for interference with endogenous transcription factors. The specificity of the 
receptors and the response elements need to be addressed such that they have all the three 
properties of an orthogonal receptor i) ligand orthogonality, where the variant protein binds 
to LG335 and is unresponsive to its natural ligand, 9cRA  ii) response element orthogonality, 
where the receptor’s DBD recognizes an artificial promoter containing the multimeric-unique 
binding sites and iii) dimerization orthogonality, where the variant protein does not dimerize 
with wild type receptors. From the library, five RXR variants were shortlisted that fulfill the 
first criteria of ligand orthogonality and were selective for LG335. To achieve the response 
element and dimerization orthogonality the RXR DBD of the variants were replaced by Gal4 
DBD to form a fusion protein, Gal4 DBD- RXR LBD (GR variant). Also, four copies of 
Gal4 RE were introduced in the promoter region of the target gene, firefly luciferase (Figure 
4.4). 
The GR variants had similar activation profile with ligands 9cRA and LG335 as 
observed with the RXR variants containing RXR DBD and LG335. GR variants I268V; 
A272V; I310L; F313M, I268A; I310A; F313A; L436F, and I268V; A272V; I310M; F313S; 
L436M have an EC50 for LG335 of 0.5 nM, 50 nM, 50 nM respectively (Figure 4.5). One 
major difference observed between GR variants and RXR variants was the high basal activity 
or leaky expression in the absence of LG335.  Due to the high basal activity there was a low 
fold induction (the ratio of maximum activation observed in the presence of ligand versus the 
activation in the absence of ligand).  The fold induction of GR variant I268V; A272V; I310L; 
F313M was 4 fold, and GR I268A; I310A; F313A; L436F, I268V; A272V; I310M; F313S; 















Figure 4.4 LG335 bound GR variants control the 
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Figure 4.5 Activation profile of the GR variants containing the RXR LBD 
and Gal4 DBD and RXR LBD in response to 9cRA and LG335 
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induction is low, the variants were tested as potential molecular switches because of their 
remarkably low EC50’s for LG335. However, the results indicate that to use these variants for 
gene therapy the high basal activity needs to be addressed.   
 
Retroviral vectors containing the GR variant I268V; A272V; I310L; F313M and the     
reporter gene 
  
To use the GR variants as molecular switches in mice the variants were cloned into a 
retroviral vector along with the reporter gene, pMSCVGR (variant)_reporter (Figure 4.6). 
The GR variant was under the control of LTR promoter and the reporter gene was under the 
control of Gal4 RE and minimal promoter as shown in figure 4.6.  The first variant cloned 
was GR I268V; A272V; I310L; F313M (GR ‘I’) with Gal4 RE driving the reporter gene, 
firefly luciferase, pMSCV GR’I’_Luc. The variant maintained a low EC50 of 5 nM for 
LG335 but had a high basal activity of 1000 RLU and low induction of 4 fold (Figure 4.7). 
To confirm the high basal activity the reporter gene was substituted from luciferase to green 
fluorescence protein (GFP). This construct contains the GR variant I268V; A272V; I310L; 
F313M with Gal4 RE driven GFP,  pMSCV GR’I’_GFP. The assay changes from 
luminescence to fluorescence. Fluorescence was observed from GFP both with and without 
LG335 (Figure 4.8). This expression of GFP along with the previous data of luciferase by 
pMSCVGR ‘I’ confirmed the leaky expression of this variant in the absence of LG335. It 
was concluded that the basal expression of the reporter gene was not due to the read through 
of the stop codon of the Gal4 DBD-RXR LBD (GR) fusion gene in the plasmid. This is 
because the luciferase activity from the cells transfected with pMSCV GR ‘I’_luc that 
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contains the GR variant and the Gal4 RE driven luciferase gene was the same as observed 
from the cells co-transfected with the two plasmids, one containing the GR variant (pMSCV 
GR ‘I’) and the other plasmid containing the luciferase gene (p17*4 Tata Luc) (Figure 4.5, 
4.7).  
 
Characterizing the GR variant I268V; A272V; I310L; F313M 
 
To understand the protein ligand interaction between GR I268V; A272V; I310L; F313M and 
LG335 and to investigate the key residues in the binding pocket of RXR that have an effect 
on EC50, activation level and high basal activity by LG335, the variant was characterized. To 
characterize the variant, single and triple mutants were made via site-directed mutagenesis 
(Stratagene, USA).  GR I268V, A272V, I310L, F313M, I268V; A272V; I310L, I268V; 
A272V; F313M, I268V; I310L; F313M, A272V; I310L; F313M were tested in mammalian 
cell culture in the presence of ligand 9cRA or LG335 (Figure 4.9). Each of the single mutants 
except GR A272V maintained a high basal activity between 1000-5000 RLU and was 
activated by both 9cRA and LG335 (Figure 4.9). Hence, none of the single mutations alone 
contributed to the ligand orthogonality, it was a cooperative effect. Triple triple mutant was 
about 1 µM with LG335 (Figure 4.10). These results show that none of the single or triple 
mutants had an EC50 as low as the quadruple mutant GR I268V; A272V; I310L; F313M at 5 
nM (Figure 4.7), nor were they as selective for LG335 over 9cRA (Figure 4.9, 4.10).   
 





































Figure 4.7 Dose response curve of the retroviral construct 
pMSCVGR I268V; A272V; I310L; F313M_luc at varying 

































Figure 4.8 Detection of fluorescence from HEK293T cells 
expressing retroviral vector, pMSCVGR I268V; A272V; I310L; 
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As an effort to decrease the basal activity (leaky expression) the co-repressor 
silencing mediator of retinoid and thyroid hormone receptor (SMRT) was transfected with 
the GR variant in HEK293T cells. Co-repressors are proteins that are recruited by RXR in the 
absence in ligand. The co-repressor in turn recruits other proteins such as histone deactylase 
(HDAC), that modify histones resulting in tighter association of chromatin, preventing RNA 
polymerase access to transcribe the DNA, hence reducing the basal expression. Upon 
addition of the ligand, the co-repressor is displaced and the target gene is expressed.   
To decrease the basal expression in the absence of ligand, equal concentration of the 
plasmid containing the co-repressor SMRT and GR I268V; A272V; I310L; F313M (40 
ng/well) was transfected in HEK293T cells. The basal expression of GR I268V; A272V; 
I310L; F313M was not significantly decreased by adding the corepressor SMRT, as the 
standard deviation of the two groups (i.e. the GR variant with or without the corepressor) 
overlap (Figure 4.11 A). Similar result was observed on adding SMRT to another GR variant 
I268A; I310A; F313A; L436F (Figure 4.11 B). Hence, addition of the co-repressor SMRT 
had negligible effect on decreasing the basal activity of GR I268V; A272V; I310L; F313M 
and this GR variant cannot be used as a potential molecular switch.   
 
Retroviral vector containing the GR variants  
 
Two GR variants I268A; I310A; F313A; L436F (GR ‘A’) and I268V; A272V; 
I310M; F313S; L436M (GR ‘B”) from the “RXR library”[14] and GR Q275C; I310M; F313I  
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Figure 4.11 Effect of corepressor SMRT on the basal activity of A) GR 
I268V; A272V; I310L; F313M and B) GR I268A; I310A; F313A; L436F 





vector, pMSCV (Figure 4.6). The retroviral vectors containing the GR variants, pMSCV GR 
(‘A’ or ‘B’ or ‘C’) were transfected in HEK293T cells with a reporter plasmid containing 
Gal4 RE driven firefly luciferase, p17*4 Tata Luc. The GR variants (‘A’ or ‘B’ or ‘C’) in the 
retroviral vector, pMSCV, induced luciferase expression similar to when they were present in 
the mammalian vector, pCMX GR  (‘A’ or ‘B’ or ‘C’) (Figure 4.5). To further investigate the 
high basal activity, the pMSCV GR (‘A’ or ‘B’ or ‘C’) were tested with reporter plasmids 
containing Gal4 RE driven GFP, p17*4 Tata GFP.  All the GR variants show negligible 
expression of GFP in the absence of ligand (Figure 4.12, 4.13, 4.14). The variant GR ‘B’ 
induces expression of GFP at 1 µM concentration of LG335 (Figure 4.13), GR ‘A’ induces 
expression at 0.1 µM concentration of LG335 (Figure 4.14) and GR’C’ induced expression at 
0.1 µM concentration of LG335 (Figure 4.12). The difference in basal expression of 
luciferase and GFP could imply that the leaky expression from the luciferase is still lower 
than the threshold required to observe a significant physiological change to express GFP.  
 
Retroviral vectors containing both the GR variants and the reporter gene 
 
To use these variants as molecular switches in mice, each GR variant ‘A’, ‘B’, ‘C’ 
was cloned into a retroviral vector along with the reporter gene, pMSCVGR (‘A’ or ‘B’ or 
‘C’) _ reporter.  The GR variant is under the control of LTR promoter and the reporter gene 
was under the control of Gal4 RE and minimal promoter (Figure 4.6). Similar luminescence 
was observed from the retroviral vectors, pMSCV GR (‘A’ or ‘B’ or ‘C’)_Luc as from the 
GR variant and reporter being in two different plasmids, pMSCV GR (‘A’ or ‘B’ or ‘C’) and 















No Ligand 10 nM LG335 
100 nM LG335 1 µM LG335 
Figure 4.12 Detection of fluorescence from HEK 293T cells transfected with retroviral 
vector containing the GR variant Q275C; F310M; F313I and mammalian expression 
plasmid containing Gal4RE driven GFP. Fluorescence is observed is at four different 















No Ligand 10 nM LG335 
100 nM LG335 1 µM LG335 
Figure 4.13 Detection of fluorescence from HEK 293T cells transfected with retroviral 
vector containing the GR variant I268V; A272V; I310M; F313S; L436M and 
mammalian expression plasmid containing Gal4RE driven GFP. Fluorescence is 















No Ligand 10 nM LG335 
100 nM LG335 1 µM LG335 
Figure 4.14 Detection of fluorescence from HEK 293T cells transfected with retroviral 
vector containing the GR variant I268A; I310A; F313A; L436F and mammalian 
expression plasmid containing Gal4RE driven GFP. Fluorescence is observed is at four 
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Figure 4.15 Activation profile of retroviral construct 
containing both the GR variants and Gal4 RE driven firefly 
luciferase in response to 9cRA and LG335. 
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activated by 9cRA and their EC50 for LG335 ranged from 50 nM – 100 nM. In addition, the 
induction varied from 6 to 10 fold. 
The low induction level is due to the high basal activity of luciferase in the absence of 
ligand. To use these variants as molecular switches they should not induced in the absence of 
ligand. To further investigate the high basal activity the luciferase gene was be replaced by 
GFP in the retroviral vector. Retroviral vectors pMSCVGR (‘A’ or ‘C’) _GFP were 
transfected in HEK293T cells. In the absence of LG335, no fluorescence was observed from 
pMSCVGR ‘A’ _GFP and pMSCVGR ‘C’ _GFP, indicating the absence of basal activity 
(Figure 4.16, 4.17). At .1 µM concentration of LG335, fluorescence was detected by both 
variants pMSCVGR ‘A’ _GFP and pMSCVGR ‘C’_GFP. With increasing concentration of 
the ligand, fluorescence from GFP increased (Figure 4.16, 4.17). The difference in basal 
expression of luciferase and GFP could mean that the leaky expression from the luciferase is 
still lower than the threshold required to observe a significant physiological change to 
express GFP. The results from GFP indicate that GR (I268A; I310A; F313A; L436F) ‘A’ and 
GR Q275C; I310M; F313I ‘B’ can potentially be used as molecular switches as it does not 
show a leaky expression and have comparatively low EC50. The next step would be to virally 
transduce these switches and regulate the expression of HOXB4 gene, to differentiation 
hematopoietic stem cells into blood and immune cells [Figure 4.18]. Efforts will be made to 




















       
No ligand 
10-6 LG335 
Figure 4.16 Detection of fluorescence from of HEK293T transfected with retroviral 
vector containing GR I268A; I310A; F313A; L436F and Gal4 RE controlled GFP in 



















No ligand 10-7 LG335
10-6 LG335 10-5 LG335
Figure 4.17 Detection of fluorescence from HEK293T transfected with retroviral vector 


















Figure 4.18 Schematic diagram showing the future application of the molecular switch 




molecular switch was created by mutating three residues in the RXR LBD via site-directed 
mutagenesis and replacing the DBD with the yeast transcription factor, Gal4 DBD.  To 
engineer a sensitive switch that has nanomolar affinity for LG335, structure-based approach 
was applied to generate a library of RXR variants. The substitutions were made on the basis 
of size, charge or hydrophobicity at six positions (I268, A271, A272, I310, F313, and L436). 
To discover the functional variants within the libraries, a genetic selection assay method 
called chemical complementation was used in yeast. The library produced ligand-receptor 
pairs with LG335 that have a variety of EC50s (40nM to > 2 µM) and activation levels (10% 
to 80% of wild-type RXR with 9cRA). The five most sensitive RXR variants I268A; I310A; 
F313A; L436F, I268V; A272V; I310L; F313M, I268A; I310S; F313A; L436F, I268V; 
A272V; I310M; F313S; L436M, and I268A; I310M; F313A; L436T were tested in 
mammalian cell culture. Out of the five, three variants I268V; A272V; I310L; F313M, 
I268A; I310A; F313A; L436F and I268V; A272V; I310M; F313S; L436M were activated by 
LG335 to a much higher level then wild type RXR. They had low EC50 for LG335 of 1 nM, 
30 nM, and 180 nM respectively and an EC50 for 9cRA of > 1 µM. These variants were then 
made orthogonal by replacing the RXR DBD by Gal4 DBD (GR variants). These orthogonal 
receptors GR I268V; A272V; I310L; F313M, I268A; I310A; F313A; L436F and I268V; 
A272V; I310M; F313S; L436M had similar activation profiles as with RXR variants 
containing the RXR DBD, with the exception of high basal activity in the uninduced state 
which results in a low induction ratio. In an attempt to reduce the basal activity, co-repressor 
SMRT was used.  Addition of co-repressor had no effect on decreasing the basal activity.  To 
introduce the GR variants in vivo, they were cloned into retroviral vectors along with a Gal4 
RE controlled reporter genes, firefly luciferase or green fluorescence protein (GFP).  One of 
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the variants I268V; A272V; I310L; F313M expressed GFP and luciferase at high levels in 
the absence of ligand. Other variants GR I268A; I310A; F313A; L436F, I268V; A272V; 
I310M; F313S; L436M and Q275C; I310M; F313I expressed luciferase gene but  no 
fluorescence from GFP was not detected in the absence of ligand. The variants had relatively 
low EC50 with LG335 and 8 to 10 induction ratio. The results suggest that GR I268A; I310A; 




The reduction in fold induction of GR variants is due to an elevated level of basal 
expression in the absence of ligand. The molecular switches can be improved by addressing 
the issue of high basal expression.  Presently, full length Gal4 DBD (residue 1-147) is 
utilized to construct the molecular switches.  GeneSwitch® inducible system, utilizes a 
chimeric regulator composed of VP16 activation domain, a truncated version of Gal4 DBD 
(residues 2-93) and mutated progesterone receptor. As an effort to decrease the basal activity 
a truncated version of Gal4 DBD can be utilized [17]. 
Higher basal expression implies that the GR variants are binding the Gal4 sites and 
are partially activating the transcription of the target gene in the absence of ligand. One 
strategy to reduce basal expression is to introduce autogeneous regulatory circuit [17]. For 
autogenous regulatory circuit the constitutive CMV promoter of the GR variant would be 
replaced by an autoinducible promoter consisting of four copies of Gal4 response elements 
linked to a minimal thymidine kinase (tk) promoter.  The minimal tk promoter will provide a 
low level of expression of the GR protein in the absence of ligand. When the ligand is added, 
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the GR variant present at a low level would get activated and bind to Gal4 RE in the 
autoinducible promoter. This would induce the synthesis of more GR variant that would in 
return activate the target gene also. Hence, introducing the autoinducible promoter may 
provide a reduction in the basal expression. 
 
Materials and Methods 
 
Constructing RXR library and plasmids  
 
The RXR library was constructed and screened by Dr Lauren Schwimmer, the details 
are mentioned in her thesis, from page 53-62 [14, 18]. The RXR variants that were activated 
with LG335 were cloned from yeast vector pGBD to mammalian vector pCMX. pCMXRXR 
variants expressing RXR DBD- RXR LBD (variant) was constructed, by cloning only the 
LBD of RXR variant from pGBD vectors using Sal I and Pst I restriction sites. pCMXGR 
variants expressing Gal4DBD fused to RXR LBD variants was constructed by cutting the 
RXR LBD variant from pGBD vector and inserting it into pCMXGRwt vector using Sal I 
and Pst I restriction enzymes. Single and triple mutants from GR I268V; A272V; I310L; 
F313M were made by either eliminating a mutation from the quadruplet to make a triple 
mutant variant or by introducing a mutation in wild type pCMXGR using oligonucleotides.  
The retroviral vector pMSCV was a kind gift from Dr Trent Spencer (Emory 
University). pMSCVGR variants were cloned from pCMXGR by amplifying Gal 4 DBD- 
RXR LBD gene using primers and inserting it via Avr II and Not I restriction sites. 
pMSCVGR variant_Luc was constructed by inserting the PCR amplified fragment of Gal4 
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RE _luciferase from p17*4 Tata luc into pMSCVGR via Not I and Sac II.  p17*4 Tata GFP 
was constructed from p17*4 Tata luc by replacing luciferase gene via Sac II and Not I 
restriction sites and inserting in GFP gene from pEGFP (Clonetech). pMSCVGR 
variant_GFP was constructed by introducing GFP gene after the Gal4 RE via Sac II and Hind 
III restriction sites in pMSCV GR variant. 
 
 Transfection protocol 
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Genetic selection is a powerful tool used in many aspects of molecular biology 
such as protein and enzyme engineering, analyzing large protein libraries, and evaluating 
macromolecular interactions[1-8]. The idea behind genetic selection is that the host cells 
will survive only if the desired function of a protein is present in the cell. Hence the 
signal to noise ratio is high which makes it efficient to evaluate protein libraries. 
Chemical complementation is a method that links a small molecule to genetic selection 
where the small molecule allows the survival of the cell. In other words, survival of cells 
is dependent on the ability of the ligand to bind and activate the nuclear receptor which in 
turn leads to the expression of a selective marker. This can be extended to various 
applications, including drug discovery and designing molecular switches for gene therapy 
and protein engineering. Recently chemical complementation was developed in our lab in 
S. cerevisiae using the strain PJ69-4A[9],[4]. This strain consists of the Gal4 response 
element (Gal4 RE) controlling expression of the ADE2 gene which encodes for 
phosphoribosylaminoimidazole carboxylase which catalyzes an essential step in adenine 
and histidine biosynthesis respectively. PJ69-4A is transformed with a library of RXR 
variants fused to the Gal4 DBD and a nuclear receptor coactivator fused to the Gal4 
activation domain (Gal4 AD).  In the presence of an agonist, the small molecule binds to 
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the RXR LBD, recruiting the coactivator Gal4 AD fusion protein initiating transcription 
of either the ADE2 or HIS3 gene.  Therefore, in media deficient in adenine, yeast cells 
will only grow in the presence of ligand.  The RXR variant that binds the ligand is 
rescued from the yeast cell and sequenced. This method is positive selection, the presence 
of the ligand induces cell growth. A negative selection method was also developed to 
eliminate the constitutively active variants that are able to turn on transcription even in 
the absence of ligand. A derivative of the PJ69-4A strain was developed called BAPJ69 
[10]. This strain contains Gal4 REs controlling the expression of ADE2, HIS3, lacZ, and 
URA3 genes (Figure 5.1). The URA3 gene codes for the enzyme orotidine-5'-phosphate 
decarboxylase (OMP) that plays a role in the uracil biosynthetic pathway. The advantage 
of using the URA3 gene is that it can function as both a positive and a negative selective 
marker.  The URA3 gene acts as a positive selective marker when the yeast cells are 
grown in uracil deficient media in the presence of ligand. The URA3 gene can also be 
used in negative selection with the use of the compound, 5’-fluoroorotic acid (5’-FOA).  
Yeast cells expressing the URA3 gene in media containing FOA, produce the enzyme 
OMP which converts the compound FOA into 5’-fluorouracil (5’-FU). 5’-FU is a toxin, 
and the yeast cells producing 5’-FU die.  Therefore, this method is termed “negative 
chemical complementation”. This technique is useful to eliminate constitutively active 
receptors from protein libraries. 
The goal here is to develop chemical complementation in mammalian cells to 
screen or genetically select for ligand-activated RXR variants. Developing chemical 
complementation in mammalian cells would eliminate the extra step of creating and 


















would eliminate the experimental discrepancy and variations observed between S. 
cerevisiae and mammalian cells. 
To develop chemical complementation in mammalian cells, a modified HeLa cell 
line has to be engineered to perform positive and negative genetic selection and screen 
for ligand activated RXR variants. To achieve this goal, HeLa cells have to be modified 
to contain a Gal4 response element controlling the expression of a triple fusion target 
gene (Figure 5.2). The target gene is a fusion of positive and negative selective markers 
and the reporter gene.  The positive selective marker is a neomycin resistant gene (Neo), 
which allows the cells expressing Neo to survive in media containing geneticin [11]. The 
negative selective marker is the thymidine kinase gene (Ttk) from the herpes simplex 
virus, which sensitizes cells to the toxic effect of the antiviral drug ganciclovir [12, 13]. 
The reporter gene is Renilla luciferase (Hrl), this gene can be assayed for luciferase 
activity and can be used to quantify the expression level. 
  The modified HeLa cell line when transfected with ligand activated RXR variants 
will initiate transcription of the triple fusion gene, Neo-Hrl-Ttk (NHT). Transfected HeLa 
cells cultured in media containing geneticin will survive only if the RXR variant is ligand 
activated and initiates transcription of the Neo gene. The transfected cells that survive the 
positive selection must contain an RXR variant that is either constitutively active or is 
activated by the agonist. To eliminate constitutively active RXR variants, the cells will be 
subjected to negative selection (i.e. negative chemical complementation). For negative 
selection, transfected cells will be cultured in media containing ganciclovir, constitutively 






Results and Discussion 
 




of thymidine kinase gene will die. Chemical complementation will leave only those cells 
containing ligand activated RXR variants or orthogonal ligand receptor pairs (Figure 5.2). 
 
Result and Discussion 
 
Constructing and testing the triple fusion gene 
 
  To perform positive and negative chemical complementation in mammalian cells 
the triple fusion gene Neo, Hrl and Ttk (NHT) was initially cloned in a commercial 
vector pBind from Stratagene, namely pBindNHT. Details about the plasmid construction 
and cloning are described in the “Materials and Methods” section.  The NHT gene is 
under the control of a strong promoter such that it is constitutively expressed and the 
functional of the Neo gene could be examined. To test the functionality of Neo gene in 
the triple fusion construct, pBindNHT was stably transfected in HeLa cells in the 
presence of geneticin. Transfected cells expressed the Neo gene and survived in media 
containing 400 µg/ml geneticin whereas the control i.e. non transfected cells died. This 
result confirmed that the Neo gene is functional in the triple fusion gene. 
The next step was to test if the Hrl gene is functional in the NHT fusion construct. The 
NHT gene was cloned into a vector containing the TATA box and four tandem repeats of 
17 bp Gal4 RE, p17*4 Tata NHT. The expression of NHT gene is controlled via a ligand 
activated RXR variant. To test the functional of the Hrl gene, HEK293T cells were 
transiently transfected with RXR variant Q275C; I310M; F313I containing the Gal4 






































Receptor: GR (QCIMFI), Reporter: Gal4 RE-Neomycin-Rluc-Thymidine Kinase
Figure 5.3  Dose response of GR Q275C; I310M; F313I  and the triple fusion 
gene construct of neomycin, luciferase and thymidine kinase (NHT) with LG335 




underwent a conformational change and initiated transcription of the NHT gene. When 
assayed for Renilla luciferase activity, a slight induction was observed in the presence of 
LG335 (Figure 5.3).  The fold activation of GR QCIMFI and Renilla luciferase in NHT 
fusion protein (p17*4 Tata NHT) is four fold. Whereas, the fold activation of GR 
QCIMFI and Renilla luciferase alone i.e. p17*4 Tata Hrl is nine fold (Figure 3.5). This 
difference in the fold induction of the NHT gene versus the Hrl gene alone is due to the 
high basal activity of the NHT gene in the absence of ligand (Figure 5.3). The reason for  
the low expression level of the Renilla luciferase gene could also be the improper folding 
of the protein. Two research groups, Oh [14] and Strathdee [15] have also constructed 
triple fusion genes with positive and negative selective markers. Strathdee and coworkers 
constructed a triple fusion gene between the hygromycin gene, GFP and thymidine kinase 
gene [15]. Oh and coworkers constructed a triple fusion gene between thymidine kinase, 
Renilla luciferase and neomycin. The Renilla luciferase activity observed in the triple 
fusion protein was only 5% of the Renilla luciferase activity when it is expressed alone 
[14]. This may mean that Renilla luciferase gene does not express very well being in the 
centre of the triple fusion gene due to the improper protein folding and hence requires 
more molecular freedom. In the future, the triple fusion gene would be constructed with 
Renilla luciferase gene being at the N- or C- terminus but for initial testing of chemical 
complementation the same triple fusion gene NHT was utilized.                                                                  
 
Testing chemical complementation in mammalian cells         
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The long term goal is to perform positive and negative chemical complementation 
in mammalian cells to screen or select protein libraries such as a library of RXR variants 
for creating ligand activated molecular switches. As a proof of principle, positive 
chemical complementation was examined by using a RXR variant that is activated by the 
ligand LG335. The RXR variant I268V; A272V; I310L; F313M containing the Gal4 
DBD (GR I268V; A272V; I310L; F313M) as mentioned in chapter 4, has a nano molar 
affinity with ligand LG335. This variant GR I268V; A272V; I310L; F313M was 
employed to test chemical complementation in mammalian cells.  
A retroviral vector containing the variant GR I268V; A272V; I310L; F313M 
followed by the Gal4 RE and the triple fusion gene NHT was constructed. The retroviral 
vector was stably transfected in HeLa cells by using 400 µg/ml geneticin and 1 µM 
LG335 in the media. Theoretically, the HeLa cells would survive only if the GR I268V; 
A272V; I310L; F313M and NHT genes are integrated in the cell’s genome and if GR 
I268V; A272V; I310L; F313M is ligand activated and initiates transcription of the NHT 
gene. After 5 days, the non transfected cells incubated with geneticin in the media died, 
whereas the transfected HeLa cells formed colonies. This result suggests successful 
integration of the genes and expression of Neo gene. To test the functional of the Renilla 
luciferase gene and the fold induction of GR I268V; A272V; I310L; F313M the cells 
were lysed and assayed for Renilla luciferase activity. There was no luminescence 
observed, suggesting that the Hrl gene in the triple fusion gene is not expressing. This 
could be because of improper folding of Hrl gene or due to integration of a truncated 






In the present study, the triple fusion gene NHT was cloned in a mammalian 
vector and was tested if the Neo and Hrl genes are functional. HeLa cells were stably 
transfected with the triple fusion gene NHT, to show that the Neo gene is working. 
HEK293T cells were transiently transfected with a plasmid containing GR variant 
Q275C; I310M; F313I and a plasmid containing a Gal4 RE driven NHT gene to show the 
that the Hrl gene is functional. Chemical complementation was tested using the retroviral 
vector containing GR variant I268V; A272V; I310L; F313M and Gal4 RE driven triple 
fusion gene. HeLa cells were stably transfected with the retroviral vector. The GR variant 
I268V; A272V; I310L; F313M activated the triple fusion gene in the presence of ligand 
and expressed the neomycin gene, but Renilla luciferase activity was not observed.  
 
Future Work  
 
To troubleshoot chemical complementation in mammalian cells the first step is to 
confirm the integration of Hrl gene in the stably transfected HeLa cells. This can be 
achieved via PCR amplification of each component of the triple fusion gene from the 
cell’s genome. The next step would be to investigate the best possible way for 
constructing the triple fusion gene between the neomycin resistant gene, Renilla 
luciferase gene and thymidine kinase gene, to improve the expression of Renilla 
luciferase. Presently, Renilla luciferase gene is in the centre of NHT gene with 
approximately twenty amino acid spacer on both ends. Different spacer lengths and 
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rearrangement of the genes can be tried such that Hrl gene is at the N or C terminal of the 
triple fusion gene and have more molecular freedom to fold properly and have better 
expression. In addition, other reporter genes such as GFP can be used instead of Renilla 
luciferase gene. 
 




Construction of plasmids expressing the RXR variants Q275C; I310M; F313I and 
I268V; A272V; I310L; F313M fused to Gal4 DBD, pCMXGR Q275C; I310M; F313I  
and pCMXGR I268V; A272V; I310L; F313M  is described in chapter 3 and 4 
respectively. The Hrl (933 bp) and Ttk (993) genes were a kind gift from Dr Gambhir 
(Stanford University). These two genes Hrl-Ttk were cloned into a commercial vector 
pDrive (Qiagen) using restriction enzymes NheI and NotI, named pDrive HrlTtk. The 
spacer between the Hrl and Ttk gene is 
ctcgagaattctcacgcgtctgcaggatatcaagcttgcggtaccgcgggcccgggatccgccacc. The Neo gene 
(801) was PCR amplified from pEGFPNeo (Clonetech) and inserted into pDrive HrlTrk 
using restriction enzymes SalI and NheI, named pDrive NHT (Figure 5.4). The spacer 
between the Neo and Hrl gene is ggcacagtcaagctcggagctagcgccacc.  To test the 
functionality of Neo in the triple fusion gene, NHT was PCR amplified from pDrive NHT 






Figure 5.4 Gene fusion between neomycin resistant gene, Renilla luciferase 
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restriction enzymes AvrII and NotI. To test the function of the Hrl gene in the triple 
fusion gene, NHT was cloned in a mammalian vector containing four repeats of 17 base 
pair Gal4 RE and a TATA box using restriction enzymes AvrII and NotI, namely 
p17*4TataNHT. To test chemical complementation in mammalian cells, a retroviral 
vector was employed, pMSCV. The GR variant I268V; A272V; I310L; F313M was 
cloned from pCMXGR I268V; A272V; I310L; F313M into the pMSCV vector using 
restriction enzymes AvrII and SalI. Four copies of the Gal4 RE and the NHT gene was 
PCR amplified from p17*4Tata NHT and inserted in the pMSCV vector. This vector 
wasnamed pMSCV GR I268V; A272V; I310L; F313M_ NHT (Figure 5.4). 
 
Testing the triple fusion gene NHT  
 
   To test the functional of the Neo gene, pBind NHT was stably transfected in HeLa 
cells by using 400 µg/ml geneticin in the media. To test the functionality of Renilla 
luciferase, HEK 293T cells were transiently transfected with p17*4 Tata NHT and 
pCMXGR Q275C, I310M, F313I. The transfected cells were incubated with varying 
concentration of LG335 and assayed for Renilla luciferase activity. To test for chemical 
complementation in mammalian cells, HeLa cells were stably transfected with the 
retroviral vector pMSCV GR I268V; A272V; I310L; F313M_ NHT  in the presence of 
400 µg/ml geneticin and 1 µM LG335. When the variant GR I268V; A272V; I310L; 





 Stable Transfection Protocol 
  
Each cell line has a different sensitivity towards geneticin. To determine the 
optimal concentration of geneticin needed for HeLa cells, different concentrations of 
geneticin were tested. The lowest concentration of drug that begins to give massive cell 
death in 3 days and kills all the cells within two weeks was choosen. For HeLa cells the 
optimal concentration was 400 µg/ml geneticin.  
After determining the optimal concentration needed for selection, HeLa cells were 
grown to 80% confluence in complete media. Cells were transfected with pBind NHT or 
pMSCV GR I268V; A272V; I310L; F313M_ NHT using Lipofectamine 2000®. After 24 
to 48 hours of transfection, the cells were split and cultured in media containing 400 
µg/ml geneticin. Cell growth was observed every 2 to 3 days and fresh medium with 
geneticin was added. After one week, cells start forming colonies and only cells 
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Identifying and characterizing protein-protein interactions are a prerequisite to 
better understand cellular mechanisms and functions. To study the dynamics, movement, 
and interactions of a protein inside living cells various techniques have been developed. 
Traditionally this has been done by in vitro labeling of proteins with fluorescent dyes and 
other molecular probes[1]. These dyes lack selectivity toward a particular protein and 
hence were attached to the protein of interest by means of antibodies to the protein of 
interest. Recent advances in genetic engineering have made it possible to track protein 
movement and interactions by fusing green fluorescent protein (GFP) and its variants to 
the protein of interest[2, 3]. However, there are major drawbacks of fluorescent proteins 
including their large size, ~27 KD, oligomerization which can affect the biological 
activity of the fused protein, photo bleaching, and low signal to background on the single 
molecule level. 
In the past decade there has been development in methodologies for studying 
interaction on the single-molecular level[4-7]. These techniques have many advantages 
over conventional ones: high sensitivity of a single molecule, the ability to show real time 
dynamics of cellular processes, and the ability to carry out assays with low quantities and 
concentrations which correspond to the natural cellular level[7-11].  Presently, there are 
two main approaches; atomic force microscopy (AFM) and fluorescence techniques. 
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AFM characterizes the forces involved in protein interaction using force spectroscopy[4, 
12]. Among the fluorescence techniques fluorescence correlation spectroscopy (FCS) is a 
powerful method for studying interaction dynamics of proteins in solution but in vivo its 
success is limited. A more robust approach is fluorescence cross-correlation of proteins 
labeled with two fluorophores. This technique has been used to monitor interactions 
within living cells [13].  Another approach for imaging interactions at interfaces on the 
single molecule level is total internal reflection fluorescence[5]. This technique has been 
applied to visualize signal transduction on the molecular level[14], and ligands binding to 
their receptors [9]. A major limitation of using the fluorescence-based single molecule 
imaging, mentioned above, is the fast photo bleaching of organic fluorophores which 
limits the observation time to a few seconds. A new technique has emerged which uses 
fluorescent quantum dots technology[7, 15]. Quantum dots are inorganic nanometer sized 
nanocrystals that contain CdSe or a CdTe core and ZnS shell. They fluoresce at sharp and 
discrete wavelengths, they have high extinction coefficients (10 to 100 times those of 
small fluorophores and FPs), and have good quantum yields. When coated, these 
quantum dots become water soluble and can be conjugated to protein targeting molecules 
such as antibodies[6, 7, 15].  
Another way to create ultra small molecular biolabels is via non-toxic hydrophilic 
dendrimer-encapsulated noble metal (DNM) nanocluster. Gold and silver nanodots have 
single molecule raman emission and show extremely strong and size-dependent single 
molecule fluorescence[8]. Here a linkage method between the DNM and the protein of 
interest is being developed. DNM will be attached to protein of interest via an amide 
bond between a cysteine residue (Cys) in the protein and the dendrimer. To test the 
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linkage method in mammalian cells, the short term goal is to use fluorescein instead of 
the DNM. Fluorescein will be linked with the protein of interest to observe the movement 
of the protein using Fluorescence Resonance Energy Transfer (FRET). 
The target protein is the nuclear receptor, retinoid X receptor (RXR) fused to 
cerulean fluorescence protein (CFP).  RXR predominantly localizes in the nucleus of the 
cell and cerulean is expressed throughout the cell. The fusion protein between RXR and 
CFP should theoretically localize in the nucleus. This protein will be attached to the 
fluorescein via N-terminal Cys. To generate the N-terminal Cys on the CFP-RXR 
construct, intein splicing technology in mammalian cells was applied. 
An intein is an internal segment of a precursor protein that is excised by a self 
catalytic mechanism, known as protein splicing, followed by ligation of the flanking 
protein regions, known as exteins[16]. To generate the N-terminal Cys an intein was 
fused to the target protein. The C-terminal of the intein will code for an Aspargine (Asn) 
and a Cys. Once expressed in mammalian cells excision will occur between the Asn and 
Cys generating an N terminal Cys on the target protein as shown in Figure 6.1[17]. 
Incubation of the cells with a thioester-containing fluorescein allows it to 
efficiently penetrate through the cell membrane into the cell. A chemo-selective ligation 
reaction occurs between the thioester of the fluorescein and the N-terminal Cys of the 
protein, giving rise to an amide bond between the fluorescein and the protein as shown in 
the Figure 6.2 and 6.3. After the protein of interest had been labeled, the next step was to 
test the linkage between the fluorescein and target protein by observing the movement of 
























intein with C-terminal 
asparagine or isoasparagine
Figure 6.1 Schematic diagram showing the mechanism of intein splicing at the C-
terminal junction of the intein with aspargine as the last amino acid of the intein 
and cysteine as the first residue of the target protein. Self cleavage generates an N- 


























Figure 6.2 Schematic diagram showing the strategy of covalent labeling of the 
protein with fluorescein (thioester tag). 
Figure 6.3 Schematic diagram showing the mechanism of chemo-selective ligation 




Figure 6.4 Pictorial diagram illustrating the absorption and emission spectrum 
in FRET   www.depts.washington.edu/chemcrs  
 
Non-FRET fluorescence occurs when a fluorophore absorbs energy at one 
wavelength, called excitation frequency and re-emits that energy at a different 
wavelength, the emission frequency. FRET imaging measures interactions between two 
proteins. Two different fluorophores are fused to the proteins of interest and each 
fluorophore has a two-peaked spectrum. The first peak is the excitation peak, and the 
second is the emission. The emission peak of the donor should overlap with the excitation 
peak of the acceptor (Figure 6.4). The advantage of FRET technology is that it has 
excellent resolution and its efficiency is dependent on the inverse sixth power of the 
distance between molecules[18]. Thus, FRET only occurs when the two fluorophores, in 
our case cerulean and fluorescein, are within 20-100Ǻ of each other, which means that 
the fluorophores must be brought together via very close protein-protein interactions. If 













CFP has an excitation wavelength of 430 nM and an emission wavelength of 480 
nm (http://www.olympusfluoview.com/applications/fpcolorpalette.html). Fluorescein has 
excitation wavelength of 480 nm and emission wavelength is of 520 nm. If fluorescein is 
indeed linked to the CFP-RXR fusion protein via the N-terminal cysteine, it will then be 
excited at the emission wavelength of CFP, proving that a probe of DNM can be linked to 
a target protein via this method. Using this technique of DNM biolabelling we will be 
able to observe the movement of RXR or other receptor such as progesterone receptor 
from the cytoplasm to the nucleus. 
 
Results and Discussion 
 
Here a linkage method between the DNM and the protein of interest is being 
developed for in vivo imaging. As a proof of principle, the linkage method is tested using 
fluorescein instead of DNM and the N-terminal Cys CFP-RXR fusion protein. If 
fluorescein is attached to the CFP-RXR fusion protein via the amide bond, allowing them 
to be in close proximity, then FRET will be observed between them. Ideally, to observe 
FRET in transfected cells incubated with fluorescein the following should happen 1) At 
430 nm, only CFP should get excited, 2) At 480 nm, only CFP should emit and 
fluorescein should be excited 3) At 520 nM, only fluorescein should emit fluorescence.  
Inherently NIH3T3 and HEK293T cells do not have background fluorescence. 
Cells transfected with the control plasmid containing only CFP gene (mCerulean from Dr 
Piston lab), emit fluorescence through out the cell when excited with the mercury lamp 
























Figure 6.5 Fluorescence images of NIH3T3 cells 
A. Transfected with mCerulean (control) showing fluorescence throughout the cell.  
B. RXR-Cerulean fusion gene showing fluorescence in the nucleus of the cell.  
C. NIH3T3 cells incubated with fluorescein showing fluorescence through out the cell. 
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fusion gene were inserted into a mammalian expression plasmid called pBind ICR 
(Stratagene). To test the functionality of CFP in the fusion gene, NIH 3T3 cells were 
transfected with pBind ICR. When excited with the mercury lamp, CFP fluorescence was 
observed only in the nucleus of the cells (Figure 6.5 B). This result indicates that the CFP 
part of the fusion gene is functional and also RXR is expressing in the fusion gene as 
CFP-RXR localizes in the nucleus (Figure 6.5 B).  The transfection efficiency of the 
pBind ICR in NIH3T3 cells was 10%.  To overcome the low transfection efficiency, 
different transfection reagents such as Polyfect®, Genejuice®, Perfectin®, 
Lipofectamine®, and Lipofectamine 2000® were tested. None of the transfection 
reagents increased the transfection efficiency of the fusion gene CFP-RXR in NIH3T3 
cells, indicating its poor expression. HEK293T cells were also tested with all the above 
transfection reagents and the best result was obtained by using lipofectamine 2000 with 
40% transfection efficiency.  
The next step was to test the emission fluorescence of cerulean and fluorescein at 
specific wavelengths. Non transfected HEK293T cells incubated with fluorescein were 
excited at two wavelengths 430 nm and 480 nm by using the excitation monochromator. 
At 430 nm, fluorescein is not excited and no fluorescence was observed between 514 nm 
to 540 nm band pass as expected (Figure 6.6). Also, at 480 nm fluorescein emits bright 
fluorescence between 514 nm to 540 nm band pass (Figure 6.6). The emission spectrum 
of fluorescein was taken using emission monochromator and the spectra looks similar to 
the theoretical spectra with peak at 514 nm (Figure 6.7).  
To test the emission fluorescence of CFP, cells were transfected with pBind ICR 
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Figure 6.6 Fluorescence from fluorescein when excited at wavelength A) 430 nm 

































































Figure 6.8 Fluorescence from cerulean when excited at 430 nm and emission at 
A) 480 nm and B) 514 nm. 
No fluorescence  




















Figure 6.9 Emission spectrum of cerulean fluorescence protein (CFP). 
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fluorescence images were observed using band filters with wavelength 480 nm and 514 
nm. Fluorescence from CFP at 514 nm was brighter then at 480 nm (Figure 6.8) which is 
opposite to what was expected. Theoretically cerulean emission spectra should peak at 
480 nm and fade around 500 nm 
(http://www.olympusfluoview.com/applications/fpcolorpalette.html). Using an emission 
monochromator the emission spectrum of cerulean was taken and an emission shift was 
observed with peak at 520nm (Figure 6.9). To observe FRET the emission spectra of the 
two fluorophores should not overlap. Emission shift of CFP from 480 nm to 520 nm 
needs to be investigated and rectified such that the pair of CFP and fluorescein can be 
utilized to test the link between them.   
 
Materials and Methods 
 
Construction of expression plasmid 
 
Retinoid X receptor was cloned in pBind plasmid (Stratagene). CFP and Ssp 
DnaB intein were PCR amplified from mCerulean (Piston Lab) and pTWIN1 vectors 
(NEB, USA) respectively, and fused to RXR, resulting in pBind Intein-CFP-RXR (pBind 
ICR). The two genes were inserted in frame after the C-terminal of Ssp DnaB intein, with 
the first amino acid of the CFP-RXR fusion protein to be cysteine residue. The last amino 
acid of the intein was aspargine (codon AAC).  
 
In vivo labeling in mammalian cells 
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Human NIH3T3 cells were grown in Dulbecco’s modified Eagle’s medium 
(DMEM, Sigma) supplemented with 10% calf bovine serum (Cellgro, USA) at  37°C 
with 5% CO2. Cells were seeded at 106 cells per six well plate on a cover slip. After 
overnight incubation, cells were transiently transfected with pBindICR or mCerulean 
using Lipofectamine 2000 (Invitrogen, USA). After 36 hours of protein expression, 
the cells were incubated with fluorescein at 5 µM concentration for five minutes. The 
cells were washed twice with 1 X PBS for five minutes, fixed with 3.6 % 
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